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Avian metapneumovirus (AMPV) causes an acute respiratory disease in turkeys and 
is associated with “swollen head syndrome” in chickens, contributing to significant 
economic losses to the US turkey industry. With a long-term goal of developing a 
better vaccine for controlling AMPV in the US, a reverse genetics system to produce 
infectious AMPV entirely form cloned cDNA was established. To achieve this, the 
unpublished sequences of the G gene, the L gene, the leader and trailer region were 
first determined to complete the entire genome sequence of AMPV subgroup C strain 
Colorado (AMPV/CO). Our results showed that the full-length AMPV/CO genome 
was 14,150 nucleotides (nt) in length, denoting that AMPV/CO possessed the longest 
genome among known metapneumoviruses. Subsequently, a cDNA clone encoding 
the entire 14,150 nt genome was generated by assembling 5 cDNA fragments, 
representing the entire genome, between the T7 RNA polymerase promoter and the 
autocatalytic hepatitis delta virus ribozyme of a low-copy number transcription 
plasmid pBR 322. Transfection of this plasmid, along with the expression plasmids 
encoding the N, P, M2-1 and L proteins of AMPV/CO, into cells stably expressing T7 
RNA polymerase resulted in the recovery of infectious AMPV/CO. The recovered 
virus was observed to contain the genetic markers that were artificially introduced 
during cloning. Characterization of the recombinant AMPV/CO showed that its 
growth characteristics in tissue culture were similar to those of the parental virus. 
These results demonstrate that infectious AMPV can be generated entirely from 
cloned DNA using reverse genetics techniques. The potential of AMPV/CO to serve 
as a viral-vector was examined using green fluorescent protein (GFP) as a reporter. 
The recovered rAMPV/CO-GFP virus stably expressed GFP for at least five serial 
passages and showed characteristics similar to that of the parental virus, except that 
there was a one-log reduction in the virus titer. These results demonstrated that the 
established reverse genetics system can be utilized effectively for various studies 
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Chapter 1: General Introduction 
 
1.1 Introduction 
Avian metapneumovirus (AMPV) causes an acute respiratory disease in turkeys 
and is also associated with ‘swollen head syndrome’ in chickens (McDougall and Cook, 
1986 ; Wilding et al., 1986; Wyeth et al., 1987; Cook et al., 1988 and Buys et al., 1989a 
and b). The virus was first isolated in South Africa in 1978 (Buys and Du Preez, 1980) 
and subsequently was isolated in Europe, Israel and Asia (Alexander, 1997; Cavanagh 
and Barret, 1988; Jones et al., 1986; McDougall and Cook, 1986 and Wilding et al., 
1986). AMPV was first isolated in the US in 1996 from commercial turkeys in Colorado 
(Kleven, 1997 and Cook et al., 1999). Subsequently, AMPV outbreaks were reported in 
Minnesota, where the disease has emerged as a major economic problem for turkey 
farmers. The mortality due to AMPV infection and concomitant secondary bacterial 
infections ranges 0–30% in the US (Alvarez et al., 2003).  
 
Based on nucleotide (nt) sequence divergence in the attachment glycoprotein (G) 
genes and their antigenic differences, AMPVs have been classified into four subgroups – 
AMPV-A, AMPV-B, AMPV-C and AMPV-D (Juhasz and, 1994; Eterradossi et al., 1995 
and Bäyon-Auboyer et al., 2000). The US isolates belong to subgroup C, and exhibit 
genetic and antigenic differences from isolates of other subgroups (Seal, 1998; Cook et 
al., 1999; Seal, 2000 and Toquin et al., 2000). The mammalian counterpart of AMPV, 
known as human metapneumovirus (HMPV), was recently isolated from children 
suffering from acute respiratory infections (van den Hoogen et al., 2001). Interestingly, 
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several reports have shown that AMPV-C has a closer resemblance to HMPV than to 
other AMPV subgroups (van den Hoogen et al., 2002; Yunus et al., 2003; Toquin et al., 
2003; Govindarajan and Samal, 2004; Govindarajan et al., 2004 and Govindarajan and 
Samal, 2005). 
 
AMPV belongs to the genus Metapneumovirus within the subfamily 
Pneumovirinae of the family Paramyxoviridae (Pringle, 1998). The viral genome is a 
non-segmented, negative sense RNA which is 14,150 nucleotides long (Govindarajan and 
Samal, 2005). The genomic RNA is organized into eight genes, with a gene order of 3′-
leader-N-P-M-F-M2-SH-G-L-trailer-5′. This differs from the gene order of the 10 genes 
of pneumoviruses such as respiratory syncytial virus (RSV), which is 3′-leader-NS1-
NS2-N-P-M-SH-G-F-M2-L-trailer-5′ (Collins et al., 1996; Ling et al., 1992 and 
Randhawa et al., 1997). The N gene encodes the nucleocapsid protein (N), which binds to 
the genomic RNA forming the nucleocapsid core. The P gene encodes the 
phosphoprotein (P) while the L gene encodes the large polymerase protein (L). Both P 
and L proteins associate with the nucleocapsid core and form the functional nucleocapsid 
within which reside the viral transcriptive and replicative activities. The M gene encodes 
the matrix (M) protein, which forms the inner layer of the envelope and is probably a 
driving force in viral assembly. The fusion protein (F) is a surface glycoprotein encoded 
by the F gene, and is involved in the fusion of the viral envelope to the cell membrane, 
thus enabling viral entry into the host cell. The M2 gene encodes two novel proteins (M2-
1 and M2-2), which are made from two open reading frames on the M2 gene. M2-1 and 
M2-2 are believed to be involved in the regulation of transcription and replication of the 
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virus (Collins et al., 1996). Small hydrophobic (SH) gene encodes the SH protein, which 
is another surface glycoprotein whose function is not completely understood. The surface 
attachment glycoprotein (G) is encoded by the G gene and is believed to be involved in 
the attachment of the virus to the cellular receptors. In AMPV/CO, G protein is 
considered to be the major determinant of host immune response towards the virus (Seal 
et al., 2000).  
 
Each gene on the AMPV genome is flanked by consensus gene-start (GS) and 
gene-end (GE) sequences and in between genes are short sequences known as the 
intergenic (IG) regions. The GS and GE regions play an important role in the process of 
transcription. Flanking the genes are the 3' extragenic region, known as the leader region 
(40 nt) and the 5' extragenic region known as the trailer region (39 nt). The leader and the 
trailer regions are believed to be the cis-acting regulatory elements involved in 
transcription, replication and packaging of the genomic as well as the antigenomic RNAs 
(Lamb and Kolakofsky, 1996). 
 
AMPV follows the same general scheme of transcription and replication as that of 
other non-segmented negative-strand RNA viruses. The N protein is always associated 
with the nucleocapsid core during the processes of both transcription and replication. The 
polymerase complex, composed of the P and L proteins, enters the genome at the 
promoter in the 3' leader region and proceeds along the length of the genome, guided 
throughout by the short regulatory GS and GE signals. A free leader RNA and eight non-
overlapping sub-genomic mRNAs are produced during this process. The IG regions are 
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not copied into the mRNAs. RNA replication occurs when the polymerase switches to a 
read-through mode, ignoring the transcription signals. This results in the production of a 
complete encapsidated positive-sense replicative intermediate, which in turn, serves as 
the template for production of progeny viral genomes. 
 
Prior to this study, nucleotide sequences of six of the eight genes of AMPV strain 
Colorado (AMPV/CO) were determined (N and P genes – Dar et al., 2001; M gene – 
Seal, 1998; F gene – Seal et al., 2000; M2 gene – Dar et al., 2003; SH gene – Toquin et 
al., 2003; Yunus et al., 2003 and Lwamba et al., 2004). The sequences of G and L genes, 
and the complete genome sequence of AMPV/CO were not established. Knowledge of 
the entire genome sequence is a prerequisite for the genetic manipulation of the virus. 
The ability to introduce genetic changes directly into negative-stranded RNA viral 
genomes has proved to have important applications in the field of molecular biology of 
viruses and also in the development of attenuated vaccine strains. 
 
Genetic manipulation of negative-sense RNA viruses has been hindered for a long 
time due to the lack of recombination in these viruses and the naked viral RNA not being 
infectious. Therefore, approaches different from those used for the positive-sense RNA 
viruses had to be developed to study genetically altered negative-sense RNA viruses. The 
most successful approach is the plasmid-complemented virus rescue system or the 
reverse genetics system. This approach is based on the cotransfection of different 
plasmids – one encoding the viral antigenome and others encoding the viral polymerase 
complex (N, P, M2 and L proteins), all under the control of T7 promoter. These 
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transfections are done in permissive cells that express the T7 RNA polymerase or cells 
infected with a recombinant vaccinia virus, which expresses the T7 RNA polymerase. 
Numerous negative-sense RNA viruses have been recovered through this plasmid-
complemented rescue system (rabies virus, Schnell et al., 1994; vesicular stomatitis virus, 
Lawson et al., 1995; human respiratory syncytial virus, Collins et al., 1995; measles 
virus, Radecke et al., 1995; Sendai virus, Garcin et al., 1995; SV5, He et al., 1997; 
rinderpest virus, Baron and Barrett, 1997; parainfluenza virus, Hoffman and Banerjee, 
1997; bovine respiratory syncytial virus, Buchholz et al., 1999 and Yunus et al., 2001; 
Newcastle disease virus, Peeters et al., 1999 and Krishnamurthy et al., 2000; human 
metapneumovirus, Biacchesi et al., 2004a and Herfst et al., 2004; and AMPV-A, Naylor 
et al., 2004).   
 
Development of a reverse genetic system for AMPV/CO would lead to the 
possibility of not only studying the functions of each AMPV gene in an authentic virus 
system, but also other aspects of basic knowledge in metapneumovirus molecular 
biology. More importantly, establishment of a rescue system will create the ability to 
directly create mutations into the cDNA and hence help in engineering a recombinant 
live-attenuated vaccine candidate. This would be particularly important for AMPV 
infections in the US, since there are no effective vaccines currently available to control 
this emerging poultry pathogen.  
 
This study is, thus, proposed to establish a rescue system for full-length AMPV 
strain Colorado, keeping in perspective the long term implications and advantages of 
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using such a system in studying the molecular biology of AMPV and generating a better 
vaccine for control of AMPV infections in the US.  
 
 
1.2 Research objectives 
The specific objectives in the present study on AMPV strain Colorado are: 
1. To determine the entire genome sequence of AMPV subgroup C strain Colorado 
(AMPV/CO) 
2. To construct AMPV/CO N, P, M2 and L gene expression plasmids and a full-length 
cDNA clone of the entire AMPV/CO genome 
3. To rescue infectious AMPV/CO from full-length cDNA clone using reverse genetic 
system 
4. To engineer AMPV/CO for the expression of a foreign gene, namely, enhanced green 







Chapter 2: Review of literature 
 
2.1 Classification 
AMPV is a member of the order Mononegavirales, family Paramyxoviridae, 
subfamily Pneumovirinae and genus Metapneumovirus (Pringle, 1998). The genome of 
metapneumovirus is a non-segmented, single-stranded, negative-sense RNA. AMPV was 
assigned to a new genus because its genome contains eight genes arranged in a different 
order from the 10 genes of members of genus Pneumovirus, such as respiratory syncytial 
virus (RSV) (Collins et al., 1996; Ling et al., 1992 and Randhawa et al., 1997). The 
newly discovered human metapneumovirus (HMPV) is the only mammalian virus that 
has been included tentatively in the genus Metapneumovirus (van den Hoogen et al., 
2001; van den Hoogen et al., 2002 and Njenga et al., 2003). 
 
AMPV subgroups A and B (AMPV-A and -B, respectively) were originally 
defined based on nucleotide sequence divergence in the attachment glycoprotein (G) gene 
(Juhasz and Easton, 1994) and antigenic differences (Toquin et al., 1992; Eterradossi et 
al., 1995 and Bäyon-Auboyer et al., 1999). In the US, AMPV was first isolated in 1996 
from commercial turkeys in Colorado (Kleven, 1997 and Cook et al., 1999). The US 
isolates of AMPV were found to be genetically and antigenically different from AMPV-A 
and -B (Seal, 1998; Cook et al., 1999 and Toquin et al., 2000) and hence were designated 
AMPV-C. Subsequently, Bäyon-Auboyer et al. (2000) isolated a new subgroup of AMPV 





AMPV are large pleomorphic enveloped virus particles ranging in size from 50 
nm to more than 200nm in diameter (Cook and Cavanagh, 2002). Internal to the viral 
envelope is the long helical nucleocapsid structure 14 nm in diameter with a pitch of 7 
nm and, externally the envelope is covered with spike glycoproteins about 15 nm long 
(Cook and Cavanagh, 2002). The nucleocapsid contains a single-stranded negative-sense 
genomic RNA of 14,150 nucleotides in the case of AMPV/CO (Govindarajan and Samal, 
2005). As encountered in all paramyxoviruses, the genomic RNA is tightly encapsidated 
by nucleocapsid protein (N), forming the nucleocapsid core. This core is associated with 
phosphoprotein (P) and large polymerase (L) protein forming the transcriptive-replicative 
complex. The envelope of AMPV contains 3 surface glycoproteins: the attachment 
glycoprotein (G) responsible for attachment of the virus to the host cell, the fusion (F) 
protein required for the fusion of the viral envelope to the host cell membrane, and the 
small hydrophobic (SH) protein, the function of which is not completely understood. In 
AMPV/CO, the G protein is considered to be the major immunogenic protein and hence 
the main target of the host-cell immune response (Seal et al., 2000). The matrix (M) 
protein lies internal to the viral envelope and is believed to be important as an organizer 
during the assembly of the virus particle (Teng and Collins, 1998). 
 
2.3 Genome organization 
AMPV genome is organized into eight genes (3′-leader-N-P-M-F-M2-SH-G-L-
trailer-5′), which are named according to the encoded protein (Fig. 1). Flanking the genes 
at the 3′ end is the leader region, which is 40 nt long and at the 5′ end is the trailer region 
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which is 39 nt long. Both leader and trailer regions are known to contain promoters and 
other regulatory sequence elements that control transcription, replication and packaging 
of the genome and antigenome (Lamb and Kolakofsky, 1996). Each gene is flanked by a 
short consensus gene-start and gene-end sequences which play a major role in 
transcription. In between two genes are intergenic regions, which range in length from 1 






Figure 1. Genome organization of AMPV. N - nucleocapsid protein gene, P – 
phosphoprotein gene, M – matrix protein gene, F – fusion protein gene, M2 – second 
matrix gene, SH – small hydrophobic protein gene, G – envelope glycoprotein gene and 





2.4 Viral proteins 
 The 8 genes of AMPV encode at least 8 proteins: N, P, M, F, M2, SH, G and L, 
unlike the pneumoviruses which encode at least 11 proteins. The M2 gene of AMPV 
encodes two proteins (M2-1 and M2-2) from two different open reading frames. These 
proteins are believed to be involved in the regulation of transcription and replication of 
the virus (Bermingham and Collins, 1999). Much of the knowledge regarding the 
functions of the AMPV proteins is derived from studies from other paramyxoviruses. 
 
2.4.1 Nucleocapsid and nucleocapsid-associated proteins 
 The nucleocapsid protein (N) is always associated with the viral genomic RNA, 
thus forming the nucleocapsid core of AMPV. The nucleocapsid functions as the 
template for the viral replication and transcription. The phosphoprotein (P) and the large 
polymerase protein (L) associate with the nucleocapsid core to form the viral  
transcriptase-replicase complex. 
  
N protein: The N protein is tightly bound around the viral genomic RNA, forming 
a RNase-resistant nucleocapsid. This nucleocapsid, in turn, associates with P and L 
proteins during transcription and replication, and most likely with the M protein during 
virus assembly. Studies based on the rhabdovirus vesicular stomatitis virus indicated that 
the intracellular concentration of the N protein may be a major factor that controls the 
relative rates of viral transcription and replication from genome templates (Blumberg and 
Kolakofsky, 1981; Blumberg et al., 1981). The complete nucleotide sequence of the N 
gene of AMPV strain Colorado (AMPV/CO) is 1206 nt long from the gene-start to the 
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gene end. The major ORF of 1188 nt contains a coding region of 394 amino acids (aa). 
The predicted molecular mass of the encoded polypeptide in the ORF is 43 kDa (Dar et 
al., 2001). Recently, an additional N polypeptide of 328 aa (molecular mass 36 kDa) was 
found to be encoded by a secondary ORF, in-frame with the major ORF, in Vero cells 
infected with AMPV/CO (Alvarez and Seal, 2005).  
  
P protein:  The P protein is highly phosphorylated and associates with the L 
protein to form the transcriptase-replicase complex. Though the large polymerase (L) 
protein is believed to possess all catalytic activities, the P protein is essential for viral 
RNA synthesis. It interacts with the N protein and keeps the latter in a soluble form and 
imparts specificity to the N protein to encapsidate viral but not cellular RNAs (Neumann 
et al., 2002). The P gene of AMPV/CO is 909 nt long and encodes a polypeptide of 294 
aa, with a predicted molecular mass of 34 kDa (Dar et al., 2001).  
  
L protein: The L protein is the largest viral protein and the least abundant of all 
structural proteins. It is the major component of the viral RNA dependant RNA 
polymerase in negative-stranded RNA viruses (Banerjee, 1987; Tordo et al., 1988). It is 
also thought to cap and polyadenylate the viral mRNAs, the latter activity is thought to be 
the result of polymerase stuttering on a short stretch of U residues. The L gene of 
AMPV/CO is 6173 nt in length from the gene-start to the gene end and encodes a 
polypeptide of 2005 aa in length. The predicted molecular mass of the polypeptide is 
228,986 Da (Govindarajan and Samal, 2004). 
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2.4.2 Matrix proteins 
 Matrix (M) protein: The M is the most abundant protein in the virion. The M 
protein is thought to be the central organizer in virus morphogenesis, due to its 
interactions with the cytoplasmic tails of the outer membrane proteins, the lipid bilayer 
and the nucleocapsids. The M protein of AMPV/CO is 868 nt long encoding a 254 aa 
long polypeptide from the longest ORF (Seal, 1998). Its predicted molecular mass is 
27,651 Da.  
  
M2 protein: The M2 protein is also known as the second matrix protein. The M2 
gene of AMPV/CO has two ORFs encoding two proteins viz. M2-1 and M2-2. These 
proteins are believed to be involved in the regulation of transcription and replication of 
the virus (Bermingham and Collins, 1999). The M2 gene of AMPV/CO is 748 nt long 
encoding two polypeptides M2-1 (14 - 569 nt) and M2-2 (525 – 740 nt) of 184 and 71 aa 
length, respectively (Dar et. al., 2003).   
 
2.4.3 Envelope proteins 
 AMPV possesses three surface envelope glycoproteins namely, the fusion (F) 
glycoprotein, the small hydrophobic (SH) glycoprotein and the attachment (G) 
glycoprotein.  
  
F protein: The F protein is a type I integral membrane glycoprotein and mediates 
pH-independent fusion of the viral envelope with the cellular membranes, following 
which the viral nucleocapsid is delivered into the cytoplasm. The F protein is synthesized 
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as an inactive precursor (F0) that is cleaved into F1 and F2 active domains by host-cell 
proteases, thus enabling the fusion process. The F gene of AMPV/CO is 1644 nt long and 
the major ORF codes for a 537 aa long polypeptide (Seal et al., 2000). The F protein of 
AMPV/CO possesses a multi-basic amino acid sequence (aa 99-KAR-aa 101) at its 
cleavage site (Seal et al., 2000). Hence, unlike HMPV, AMPV/CO is capable of growing 
in tissue culture without the addition of exogenous trypsin.  
  
SH protein: The SH protein is a type II integral membrane glycoprotein whose 
precise function is not completely known. It was suggested that SH protein of human 
respiratory syncytial virus (RSV) possesses characteristics of a viroporin, which modifies 
membrane permeability (Gonzalez and Carrasco, 2003). The RSV SH protein has also 
been implicated in impairing the Th1-medicated host antiviral responses (Tripp et al., 
2000). The AMPV/CO SH gene is 623 nt long and encodes a 175 aa long polypeptide 
(Toquin et al., 2003). 
  
G protein: The G protein of metapneumoviruses is believed to be the putative cell 
attachment protein. It is also considered to be the major antigenic determinant of 
AMPV/CO (Seal et al., 2000). The AMPV G protein is a type II membrane glycoprotein, 
containing an N terminal intracellular domain, a short transmembrane domain and a C 
terminal extracellular domain. The G protein of AMPV/CO is 1798 nt long from gene 
start to gene end, encoding a predicted polypeptide of 585 aa. The predicted molecular 
mass of the G protein of AMPV/CO was 58754 Da with a significantly high content of 
G+C residues (Govindarajan et al., 2004). 
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2.5 Stages of AMPV replication 
 AMPV follows the same pattern of replication as other paramyxoviruses, which is 
described in the following sections.  
 
2.5.1 Adsorption and entry 
 Initiation of infection starts with the adsorption of the virus to the cell surface 
receptors and subsequent fusion of the viral envelope to the cell membrane. The former is 
mediated by the G protein while the latter by the F protein. The precise nature of the 
cellular receptor that is involved in AMPV infection has not been identified. The viral 
nucleocapsid is then delivered into the cytoplasm and all stages of AMPV replication 
occur in the cytoplasm. 
 
2.5.2 Transcription 
 The pattern of transcription of the AMPV genome is consistent with that proposed 
for all nonsegmented negative stranded RNA viruses. By analogy to other viruses, the 3' 
leader region on the AMPV genome acts as the polymerase entry site and is recognized 
by the viral polymerase complex. The viral RNA polymerase first transcribes the leader 
RNA (uncapped and untailed) and then makes capped and polyadenylated viral mRNAs, 
guided by the conserved transcriptional start and stop sequences of each gene. 
Transcription continues in this start-stop fashion until the L mRNA is synthesized. The 
intergenic regions located between the individual genes are not transcribed during this 
process. Since the frequency with which the viral polymerase restarts mRNA synthesis at 
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each gene junction varies, the upstream genes are always transcribed more than the 
downstream genes leading to a gradient of mRNA abundance (Fig. 2). 
 
2.5.3 RNA Replication 
 AMPV probably follows the same general mode of RNA replication as observed 
in other nonsegmented negative-sense RNA viruses. After primary transcription and 
translation of mRNAs, genome (-) replication starts with the synthesis of a full-length 
complementary copy known as the antigenome (+). The newly synthesized antigenome 
serves as the template for the synthesis of new progeny viral genomes (Fig. 2). During 
RNA replication, the viral polymerase follows a read-through process ignoring the 
transcription start and stop signals, thus leading to the formation of a faithful complement 
of the genome. Both the genome and antigenome are assembled into encapsidated 
nucleocapsids. The leader and trailer regions of the genome are assumed to contain 
specific sequences for encapsidation (Blumberg and Kolakofsky, 1981). The precise 
reason for the switching of the polymerase from transcriptive to replicative mode is not 
clearly known. The coupling of genome assembly/encapsidation and genome synthesis is 
believed to cause the polymerase to ignore the junctional and editing signals (Kolakofsky 
et al., 1991). In RSV, it was observed that though increased levels of N stimulated 
replication there was no evidence of a switch from transcription to replication (Fearns et 
al., 1997). However, M2-2 protein has also been observed to have a regulatory role in 












Figure 2. Schematic of AMPV transcription and replication. Genome and antigenome are 
shown as nucleocapsids with ovals representing the N protein subunits and vertical lines 
indicating the gene junctions. P-L complex transcribes the genome generating capped and 
poly A-tailed mRNAs. When sufficient viral protein levels are achieved, the viral 
polymerase switches to replicative mode resulting in the production of an antigenome, 






2.5.4 Packaging and release 
 The nucleocapsid assembly occurs in the cytoplasm of infected cells. The 
mechanism of viral assembly and release of AMPV is probably similar to that of other 
paramyxoviruses. Encapsidation of the viral genomic RNA into the nucleocapsid is the 
first step in viral assembly. The formation of the nucleocapsid occurs in two steps: first, 
the free N protein subunits associate to the genomic RNA to form the helical 
ribonucleoprotein, followed by the association of the P-L protein complex (Kingsbury et 
al., 1978). The accumulation of the M protein may also be crucial for initiating the 
assembly of virions (Teng and Collins, 1998). The viral envelope is assembled at the cell 
surface. The integral membrane glycoproteins (F, SH and G) are synthesized in the 
endoplasmic reticulum and then transported to the cell surface by the cellular secretory 
pathway. The nucleocapsid complex/M-protein structure, then associates with the 
cytoplasmic tails of the glycoproteins that are inserted into the cell membrane (Easton et 
al., 2004). Finally, release of the virus takes place by budding from the plasma 
membrane. 
 
2.6 Avian metapneumovirus infections 
 
2.6.1 Prevalence of AMPVs 
 AMPV virus was first isolated in South Africa in 1978 from turkeys exhibiting 
signs of sinusitis (Buys and Du Preez, 1980). Subsequently, presence of the virus was 
reported in United Kingdom (McDougall and Cook, 1986 and Wilding et al., 1986), 
France (Giraud et al., 1986 and Bäyon-Auboyer et al., 2000), Germany (Naylor and 
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Jones, 1993), Netherlands (Cook et al., 1993), Japan (Tanaka et al., 1995 and Mase et al., 
2003), Mexico (Decanini et al., 1991), Israel (Weisman et al., 1988 and Banet-Noach et 
al., 2005), Morocco (El Houadfi et al., 1991), Brazil (Arns and Hafez, 1992 and D’Arce 
et al., 2005) and Chile (Toro et al., 1998). AMPV was first isolated in the US in 1996 
from commercial turkeys suffering from rhinotracheitis in Colorado (Kleven, 1997 and 
Cook et al., 1999). Currently, the subgroups A and B of AMPV are prevalent in Europe, 
United Kingdom, Japan, Brazil and Israel. Subgroup C in prevalent in many states of the 
US and Canada and the new subgroup, subgroup D is prevalent in France. 
 
2.6.2 Disease in poultry 
AMPV infections in poultry are essentially acute respiratory infections 
characterized by coughing, sneezing, and swelling of the infraorbital sinuses and other 
signs of respiratory distress often associated with nasal and ocular discharges. The 
disease has a high morbidity rate but the mortality rate ranges from 0 to 30% that may 
increase further with secondary bacterial infections. The clinical signs observed are more 
severe in birds infected with AMPV and other bacterial agents than with the virus alone 
(Alkhalaf et al., 2002; Jirjis et al., 2004 and Marien et al., 2005). Though turkeys and 
chicken are the main species of birds affected, the virus can also infect other species of 
birds (reviewed by Njenga et al., 2003). 
 
2.6.3 Current control strategies 
 Currently, both live attenuated and killed vaccines are being used to control 
AMPV infections in Europe (Cook, 2000). However, in the US the killed vaccines have 
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not proven to be effective to control AMPV infections (Sheikh, 2001). A high-passage 
virus was observed to provide protection to turkey poults in response to immunization 
(Gulati et al., 2001). Studies have shown that cold-adapted AMPV can be used as a live 
attenuated vaccine and can prove to be safe and effective (Patnayak et al., 2002; Patnayak 
et al., 2003 and Patnayak and Goyal, 2004). A DNA vaccine expressing the F protein of 
AMPV was observed to reduce clinical symptoms in challenged birds better than one 
expressing the N protein (Kapczynski and Sellers, 2003). A virosome vaccine against 
AMPV was also observed to provide some level of protection following challenge 
(Kapczynski, 2004). However, the molecular basis of attenuation is unknown in the 
current vaccines being used in the US.  
 
2.7 Minigenome and virus rescue systems for metapneumoviruses 
 Genetic manipulation of negative-stranded RNA viruses has been difficult, unlike 
the positive stranded ones. The major reasons for this are (1) lack of detectable genetic 
recombination in the negative sense RNA viruses and (2) the naked RNA is not infectious 
by itself. However, with the development of a reverse-genetic system, it is possible to 
introduce genetic changes directly into the negative-stranded RNA viral genome. This 
has significant applications in molecular biology studies as well as for the development 
of potential recombinant vaccines. The initial approach to genetically manipulate the 
genomes of negative-sense RNA viruses has been the “minigenome” system. A 
minigenome essentially consists of a synthetic construct made of genomic terminal 
sequences abutting a reporter gene. This is transcribed in vitro and then transfected into 
cells infected with the helper virus. A second approach involved the use of the support 
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plasmids (the nucleocapsid proteins) using the transient recombinant vaccinia virus/T7 
RNA polymerase expression system, thus avoiding infection with the wild type helper 
virus. Since these minigenome systems do not represent the full-length genome, the main 
challenge was to rescue full-length genome RNAs.  
 
The plasmid based approach has been utilized to recover infectious recombinant 
virus from full-length cDNA for several non-segmented negative-strand RNA viruses, 
namely rabies virus (Schnell et al., 1994), vesicular stomatitis virus (Lawson et al., 1995), 
measles virus (Radecke et al., 1995), rinderpest virus (Baron and Barrett, 1997), 
parainfluenza virus (Hoffmann and Banerjee, 1997), Newcastle disease virus (Peeters et 
al., 1999 and Krishnamurthy et al., 2000) and many other viruses. Among the members 
of subfamily Pneumovirinae, HRSV was the first to be recovered by reverse genetics 
system (Collins et. al., 1995). Subsequently, a virus rescue system was also established 
for the bovine respiratory syncytial virus (Buchholz et al., 1999 and Yunus et al., 2001). 
 
 
2.7.1 Rescue systems for avian metapneumoviruses 
Among the avian metapneumoviruses, a minigenome system was first developed 
for AMPV-A strain CVL14/L (Randhawa et al., 1997). This minigenome system, 
containing the chloramphenicol acetyl transferase (CAT) gene as the reporter gene, 
utilized T7 RNA polymerase runoff transcripts transfected into AMPV-infected cells. 
Using this system it was established that NS1 and NS2 genes were absent from the 
genome of avian metapneumovirus. Recently, a reverse genetics system developed for 
AMPV-A strain LAH A demonstrated that the SH and the G genes were not essential for 
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virus survival in vitro (Naylor et al., 2004). Complete genome sequences of AMPV 
subgroups B and D are currently not available and hence development of a reverse 
genetics system for these viruses has not been possible.   
 
2.7.2 Rescue systems for human metapneumoviruses 
 
The first full-length HMPV to be recovered entirely from cloned cDNA was the 
Canadian isolate CAN97-83 (Biacchesi et al., 2004a). Subsequently, two isolates, 
NL/1/00 and NL/1/99, representing lineages A and B, respectively, were also recovered 
(Herfst et al., 2004). This recently established rescue system for HMPV has paved way 
for numerous studies related to HMPV molecular biology, pathogenesis and vaccine 
development. A recombinant HMPV expressing GFP as a foreign protein showed that the 
HMPV can also serve as a vector for foreign gene expression (Biacchesi et al., 2004a). In 
addition, GFP expression in living cells greatly helped in monitoring the initial recovery 
of these viruses by fluorescent microscopy. A recombinant HMPV that expressed an 
additional G gene and 2 additional copies of F gene indicated that the HMPV genome can 
be manipulated with relative ease and can accommodate up to a 30 % increase in length 
(Biacchesi et al., 2004a). Both the SH and G genes, alone or together, were observed to 
be dispensable for growth of HMPV in tissue culture as well as in respiratory tract of 
hamsters (Biacchesi et al., 2004b). Deletion mutants of HMPV lacking M2-1, M2-2, 
either individually or together, showed that though both of them are not required for in 




Chapter 3: Determination of complete genome sequence 
 
 
This chapter deals with the determination of the nucleotide sequences of 
attachment glycoprotein gene (Govindarajan et al., 2004), large polymerase protein gene 
(Govindarajan and Samal, 2004), and the leader and trailer regions of AMPV strain 
Colorado (AMPV/CO). Hence, with the previously determined sequences, this completes 
the entire genome sequence of AMPV/CO (Govindarajan and Samal, 2005).  
 
3.1 Abstract 
 The nucleotide sequences of the G gene, L gene, and the genomic termini of 
AMPV/CO were determined. The G gene was 1798 nucleotides long and encoded a 
polypeptide of 585 amino acids. It was the longest G gene among all known 
metapneumoviruses. The L gene was 6173 nucleotides long and encoded a polypeptide of 
2005 amino acids. Both the genes and their deduced proteins showed higher levels of 
identities to the corresponding genes and proteins of HMPV than to those of other 
AMPVs. The sequences of the 3' leader and the 5' trailer regions were determined to be 
40 and 39 nucleotides long, respectively. Comparison of the genomic termini sequences 
indicated that there was high level of conservation among the metapneumoviruses and the 
genomic termini of AMPV/CO were more similar to those of the HMPVs than to the 
AMPVs. This study completes the sequence of the 14150 nucleotide genomic RNA of 





 AMPV is a member of the genus Metapneumovirus in the subfamily 
Pneumovirinae of the family Paramyxoviridae (Pringle, 1998). The virus contains a non-
segmented, single-stranded, negative-sense RNA genome with eight genes encoding at 
least nine proteins (Ling and Pringle, 1988 and Yu et al., 1992): the nucleocapsid protein 
(N), the phosphoprotein (P), the matrix protein (M), the fusion protein (F), the second 
matrix proteins (M2-1 and M2-2), the small hydrophobic protein (SH), the attachment 
glycoprotein (G) and the large polymerase protein (P). Flanking the genes are the 3' and 
5' extracistronic regions, known as the leader and trailer, respectively. These regions have 
been believed to be the cis-acting regulatory elements in replication, transcription and 
packaging of the genomic and antigenomic RNA (Lamb and Kolakofsky, 1996).  
  
The nucleotide sequences of all eight genes of AMPV-A have been determined 
(Randhawa et al., 1997 and references therein). All of the genes except for the L gene of 
AMPV-B have also been sequenced (Jacobs et al., 2003 and references therein). 
Nucleotide sequences of six genes of AMPV/CO, namely N (Dar et al., 2001), P (Dar et 
al., 2001), M (Seal, 1998), F (Seal et al., 2000), M2 (Dar et al., 2003) and SH (Yunus et 
al., 2003; Toquin et al., 2003 and Lwamba et al., 2004) have been reported. However, 
there have been conflicting reports on the length of the G gene of AMPV/CO. The G 
gene of AMPV/CO was reported to be 1321 nt long with a predicted polypeptide of 
435 aa (Alvarez et al., 2003; GenBank accession no. AY579780) or 783 nt long with a 
predicted polypeptide of 252 aa (Toquin et al., 2003; GenBank accession no. AJ457967). 
In both of these studies, G gene sequences were obtained from the genomic RNAs of 
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AMPV/CO. In our study, G gene sequences were obtained by sequencing the genomic 
RNAs and mRNAs of three different strains of AMPV-C. 
 
The availability of a complete sequence of AMPV/CO genome is essential to 
rescue infectious virus entirely from cloned cDNA. And, the development of a rescue 
system for this virus should stimulate further research towards a complete understanding 
of this emerging turkey pathogen. Hence, with the ultimate goal of developing a rescue 
system, we report here the remaining undetermined sequences of AMPV strain Colorado 
and compare them to related viruses. These sequences include the complete G gene, L 
gene, and the entire leader and trailer regions. 
 
3.3 Materials and methods 
 
3.3.1 Cells, virus and RNA extraction 
 AMPV-C strain Colorado (AMPV/CO), obtained from the National Veterinary 
Services Laboratory (Ames, Iowa), was grown in Vero cells supplemented with 2% fetal 
bovine serum. AMPV-C strains Mn-1a and Mn-2a (used to determine the G gene 
sequence) were kindly provided by Sagar M. Goyal (University of Minnesota, St Paul, 
MN, USA).The virus propagation, purification and RNA extraction were performed in a 
manner similar to those described elsewhere (Govindarajan and Samal, 2004). Briefly, 
Vero cells were infected with AMPV/CO and the virus was harvested when maximum 
cytopathic effect was evident as extensive syncytia. The infected cells were scraped into 
the medium and lysed by three cycles of freezing and thawing to release the intracellular 
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virus. The cell lysate was clarified at 3000 g for 15 min, and the supernatant was made 
10% with respect to PEG 8000 (Sigma) and incubated for 3 h at 4 °C. Subsequently, the 
virus was pelleted at 4000 g for 30 min at 4 °C. Viral genomic RNA was extracted from 
the viral pellet using TRIzol reagent (Invitrogen) according to the manufacturer’s 
protocol, except that an additional extraction with phenol plus chloroform was 
performed. Viral mRNAs were isolated from infected Vero cell lysates by using a polyA 
Spin mRNA Isolation kit (New England Biolabs). 
 
3.3.2 Reverse transcription and PCR 
 G gene: The "genome walking" strategy was initially employed for obtaining the 
complete sequence of the G gene. AMPV genomic RNA was reverse transcribed at 42 °C 
using Superscript II reverse transcriptase (Invitrogen) and a G gene-specific positive-
sense primer, G-513 (5'-CACAAGCAATAGCACAACTGACAACACCAACAAC-3'). 
The cDNA synthesized from the above reverse transcription reaction was purified using a 
PCR purification kit (Qiagen) and then used for PCR amplification using G-513 and an L 
gene-specific negative-sense primer, L-713 (5'-GGCCCCTTGTAAATTGCTTCTAA-3'); 
the primer sequences were obtained from the published G gene sequence (Toquin et al., 
2003). Although a single, sharply defined amplification product was not obtained from 
this PCR, the obtained product was cloned and subsequently sequenced. Surprisingly, 
sequence analysis of numerous clones did not yield a single consensus sequence; instead, 
consensus sequences were obtained at the 5' and 3' ends of the cDNA clones, whereas the 
internal regions varied in length. As numerous attempts to determine the complete G gene 
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sequence from the viral genomic RNA proved unsuccessful, we decided to use the G 
mRNA as a template to determine the complete G gene sequence. 
 
All RT reactions of mRNAs isolated from virus-infected cells were performed by 
using a ProtoScript First Strand cDNA Synthesis kit (New England Biolabs). Three 
separate RT reactions were performed for each virus, using an oligo(dT) primer and two 
G gene-specific reverse primers, G-1589 (5'-CAGTGCCGTCCCCAAAACAT-3') and G-
1640 (5'-CATCATAGCAACCAGCCGGC-3'), which were designed based on the 
sequence obtained from viral genomic RNA. PCR was performed with TaKaRa LA Taq 
polymerase and GC buffer II (TaKaRa), using primers G-513 and G-1589. The following 
cycle parameters were used in the PCR: initial denaturation at 94 °C for 1 min, 30 cycles 
of 94 °C for 30 s, 60 °C for 30 s and 72 °C for 2 min, and a final elongation step of 72 °C 
for 5 min. This PCR yielded a single 1·1 kb product. RT-PCR of mRNAs isolated from 
uninfected cells by using the same primers did not yield any product. The entire RT-PCR 
was performed three times, each time with a new viral mRNA preparation, and each time 
a single product of 1·1 kb was amplified. These products were either sequenced directly 
or were cloned and subsequently sequenced to yield the complete sequence of the G 
gene. 
 
L gene: To determine the complete sequence of the L gene, the "genome 
walking" strategy was employed. AMPV genomic RNA was reverse transcribed at 42 °C 
using Superscript II reverse transcriptase (Invitrogen) and an L gene-specific positive-
sense primer (5′-TAAAAATGGATCCACTAAATGAAGG-3′). The primer was 
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designed using the published partial L gene sequence of AMPV-C (Toquin et al., 2003). 
The c-DNA synthesized from the above reverse transcription reaction was purified using 
a PCR purification kit (Qiagen), then tailed with C nucleotides in a tailing reaction 
catalyzed by terminal deoxynucleotidyl transferase enzyme (Invitrogen). The dC-tailed 
cDNA was used for PCR amplification using L gene-specific forward primer, a poly dG-
anchor reverse primer (Invitrogen) and Platinum Pfx polymerase (Invitrogen).  
 
Leader region: As the leader and trailer regions of AMPV-A showed high 
resemblance to those of HMPV isolate 00-1 (van den Hoogen et al., 2002), we designed 
consensus primers to obtain the sequence of the AMPV/CO leader and trailer regions. To 
obtain the 3′ leader sequence, the AMPV/CO genomic RNA was reverse-transcribed with 
a positive-sense consensus leader primer, le-For (5′ GGAGGACGAGAAAAAAACGC 
3′). The resulting cDNA was subjected to a PCR with le-For primer and an N gene-
specific negative-sense primer, N-540 (5′ GATTGTTGATGCCAGCTTCGTGAA 3′). 
The PCR product thus obtained was cloned and the clones were hybridized with an N 
gene-specific radiolabelled probe. The 3′ leader sequence was obtained from nt 
sequencing of numerous hybridization-positive clones. To further confirm the leader 
sequence, viral RNA was polyadenylated at its 3′ end using poly A polymerase 
(Invitrogen) and reverse transcribed with an oligo dT primer. PCR was performed using a 
GeneRacer 3′ forward primer (GeneRacer kit, Invitrogen) and the above-described N-540 
primer. The amplified cDNA was either directly sequenced or cloned and several clones 




Trailer region: The sequence of the 5′ trailer region was also obtained using the 
method described for obtaining the sequence at the 3′ leader region. Briefly, the 
AMPV/CO genomic RNA was reverse-transcribed with an L gene-specific positive-sense 
primer, L-5787 (5′ GTTGGAGGCAGCAGGGTCATAGAATC 3′) and a PCR was 
performed with L-5787 and a negative-sense consensus trailer primer, tr-Rev (5′ GGAG- 
GACGAGAAAAAAACCGTAT 3′). The resulting RT-PCR product was either directly 
sequenced or cloned and sequenced to obtain the sequence of the 5′ trailer region of 
AMPV/CO. The sequence of the 5′ trailer region was further confirmed using the 5′ 
RACE method (Krishnamurthy and Samal, 1998). The cDNA from the L-5787 RT 
reaction was tailed with dCTP using terminal deoxynucleotidyl transferase (Invitrogen), 
and PCR-amplified with L-5787 and an oligo dG anchor primer (Invitrogen). The PCR 
product was then cloned and several clones from three independent 5′ RACE reactions 
were sequenced to obtain the sequence of the 5′ trailer region of the AMPV/CO genome.  
 
3.3.3 Cloning and sequencing 
G gene: The PCR amplicons were either sequenced directly or were cloned and 
subsequently sequenced using an ABI 3100 DNA sequencer (Applied Biosystems). The 
PCR-amplified products were cloned into a TOPO-Zero blunt cloning vector (Invitrogen) 
and transformed into DH10B maximum efficiency competent cells (Invitrogen). Several 
colonies were sequenced and the correct sequence was obtained from sequences derived 
from at least three independent reactions. All sequencing procedures to determine the G 
gene sequence were performed in the presence of 5 % (v/v) DMSO or 1 M betaine (final 
concentration) in the sequencing reaction mixture. The sequences obtained from RT-PCR 
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products made from genomic and mRNAs were assembled to yield the complete 
sequence of the G gene. 
  
L gene: The PCR-amplified products from the L gene were cloned as described 
above. The resulting colonies were hybridized with a radiolabelled L cDNA probe 
representing the first 713 nt of the L gene. Several hybridization-positive colonies having 
larger size inserts were selected and sequenced. The correct sequence was obtained from 
sequences derived from at least three independent clones. The entire sequence of the L 
gene was obtained by repeating the cloning and sequencing procedures. The L gene 
sequence obtained from each round of cloning was used to design the forward primer for 
the next round of RT-PCR. The RT-PCR products were also sequenced directly without 
cloning to derive at the consensus sequence. 
  
3.3.4 Sequence analyses 
 All the sequence analyses were performed using the DNASTAR software 
program. Complete genome assembly was performed with the Seqman tool of the 
software and all the protein alignments were carried out using the ClustalW method 
(www.ebi.ac.uk/clustalw). Phylogenetic trees were constructed using the DNASTAR 
software program, while the lengths of distances between the sequences were obtained 









3.4.1 G gene sequence 
The complete G gene of AMPV/CO was 1798 nt (GenBank accession no. 
AY590691) from the start to the end of the gene, encoding a predicted polypeptide of 
585 aa. The length of the G gene determined by us was 1015 nt longer than that reported 
previously for the same AMPV/CO strain (Toquin et al., 2003). To determine whether the 
lengths and sequences of the G genes were conserved among strains of AMPV-C, we 
cloned and sequenced the G genes of AMPV-C strains Mn-1a and Mn-2a. We observed 
that the gene length and the predicted protein length of G genes of Mn-1a and Mn-2a 
were exactly the same as those of AMPV/CO, but that considerable sequence variation 
existed between the two strains (Fig. 3).  
 
The G gene of AMPV/CO, as observed for other metapneumoviruses, possessed 
the highly conserved gene-start (5'-GGGACAAGU-3', mRNA sense) and gene-end (5'-
UAGUUAAUUAAAAA-3') signals (Ling et al., 1992 and Biacchesi et al., 2003). Apart 
from the major ORF, four potential secondary ORFs (ORF2, 146–1771 nt, 541 aa; ORF3, 
155–1771 nt, 538 aa; ORF4, 167–1771 nt, 534 aa; and ORF5, 1312–1608 nt, 98 aa) were 
also observed in the G gene of AMPV/CO. The G genes of Mn-1a and Mn-2a also 
contained similar secondary ORFs. 
 
        Intra-cellular domain        Transmembrane domain        Extra-cellular domain 
         ├-----------------------------------------------------┤├-------------------------------------┤├-------------------------------------------------------------- 
 
AMPV/CO   MEVKVENVGKSQELKVKVKNFIKRSDCKKKLFALILGLVSFELTMNIMLSVMYVESNEALSLCRIQGTPAPRDNKTNTENATKETTLHTT      90 
Mn-1a     ..........................................................................................      90 
Mn-2a     ..........................................................................................      90 
  
AMPV/CO   TTTRDPEVRETKTTKPQANEGATNPSRNLTTKGDKHQTTRATTEAELEKQSKQTTEPGTSTQKHTPTRPSSKSPTTTQAIAQLTTPTTPK     180 
Mn-1a     ..........................................................................................     180 
Mn-2a     ..................................................................A............T..P....A..     180 
 
AMPV/CO   ASTAPKNRQATTKKTETDTTTASRARNTNNPTETATTTPKATTETGKSKEGPTQHTTKEQPETTAGETTTPQPRRTASRPAPTTKIEEEA     270 
Mn-1a     ............................DS..G...A....AA.A................GA.....A.....................     270 
Mn-2a     ...............................................G.................R........................     270 
  
AMPV/CO   ETTKTRTTKSTQTSTGPPRPTGGAPSGAATEGSGRAAAAGGPSAASAGGRRRTEAAAERDRRTRAGAGPTAGGARARTAAASERGADTAG     360 
Mn-1a     ..........................................................................................     360 
Mn-2a     .........N...........RST..KT...NNK.TTTTKR.NT..TDS.QQ.RIT..Q.QQ.QTR.K..TN..HPQ.TTTP.HNT..TN     360 
  
AMPV/CO   SAGGGPGGDGATGGLSGGAPAEREDASGGTAAAGPGDGTEADGRAPPAAALAGRTTESAAGAAGDSGRAGTAGWGSAADGRSTGGNAAAE     450 
Mn-1a     .......................G..................................................................     450 
Mn-2a     .TK.S.KE.KT.RDP.SKT.T.Q....K.....N..GSA...R.....TTPT.........TT..DSG.E.TRRR....R.....ST...     450 
                                                                  
AMPV/CO   AGAAQSGRAAPRQPSGGTAPESTAPPNSGGSGRADAAPTEEVGVGSGLWRGRYVCGPCGESVPEHPMNPCFGDGTAWICSDDGGSLPAGC     540 
Mn-1a     ..........................................................................................     540 
Mn-2a     ..T......T.K.......AGN.....NES........A.......SI..........R...L..................G..N.....     540 
  
AMPV/CO   YDGGTDGVVCCGVCGGNSCCCGRVECTCGGGAGLLSCCCGSYSWS     585 
Mn-1a     .............................................     585 
Mn-2a     ..S.A.......I.............................N..     585  
 
 
Figure 3. Comparative alignment of the deduced amino acid sequences of the predicted G proteins of AMPV-CO, Mn-1a and Mn-2a. 
Proposed intracellular, transmembrane and extracellular domains of the G proteins are indicated above the sequences. Conserved 
amino acids relative to AMPV/CO are indicated by dots and potential N-linked glycosylation sites are underlined. The residues 
forming the hypervariable region (aa 300–450) on Mn-2a G protein have been highlighted in bold. 
The predicted molecular mass of the G protein of AMPV/CO was 58 754 Da, 
having a net charge of 8·27 at neutral pH and an isoelectric point of 8·28. The G+C 
content of the G gene of AMPV/CO was 61 mol%, which was significantly higher than 
that of the G genes of other metapneumoviruses. The additional 1015 nt determined by us 
in the G gene of AMPV/CO had a much higher G+C content (73 mol%). The amino acid 
composition of the deduced G protein of AMPV/CO was relatively similar to those of 
other AMPV G proteins (Table 1). The G protein of AMPV/CO contained 7·2 % proline 
and 23·1 % serine/threonine residues, a consistent feature of mucin-like glycoproteins. 
The predicted G proteins of the three AMPV-C strains contained three conserved, 
potential N-linked glycosylation sites (Fig. 3). Seventy eight predicted potential O-linked 
glycosylation sites were observed on the G protein of AMPV/CO where as Mn-1a and 
Mn-2a G proteins possessed 74 and 103 predicted O-linked glycosylation sites.  
However, by analogy to HRSV and HMPV, it is unlikely that all of these sites are used. 
Majority of these sites were observed to lie between aa residues 150-300 (the predicted 
extracellular domain) in all the three viruses.  The G ORFs of the three AMPV-C strains 
contained 18 conserved cysteine residues, 17 of which were present in the extracellular 
domains. 
 
Hydropathy analysis of the putative G proteins of AMPV/CO, Mn-1a and Mn-2a 
showed characteristics of an anchored, type II membrane glycoprotein. The predicted 
hydrophobicity profile of AMPV/CO G protein included an amino-terminal, hydrophilic 
intracellular domain (aa 1–31), a hydrophobic transmembrane domain (aa 32–54) and a 































































































































AMPV/CO showed structural and biochemical features similar to those of the HMPVs, it 
showed only 23, 25 and 21 % amino acid identity to the corresponding proteins of 
HMPV-001, CAN97-83 and CAN98-75, respectively. However, the levels of amino acid 
identity to the G proteins of other AMPV subgroups were still lower: 14 % to those of  
AMPV-A and -B and 16 % to that of AMPV-D. Among the US strains, the G protein of 
AMPV/CO showed 98 and 81 % amino acid identity to those of Mn-1a and Mn-2a, 
respectively. The predicted G proteins of Mn-1a and Mn-2a exhibited 79 % amino acid 
identity between themselves. Sequence alignment of the G genes of the three AMPV-C 
strains revealed that Mn-1a and Mn-2a possessed 21 and 195 nt substitutions relative to 
AMPV/CO, resulting in 11 and 110 aa changes, respectively, in their deduced proteins. 
The majority of the changes in the predicted G protein of Mn-2a lay between aa 300 and 
450, thus forming a hypervariable region with only 48 % amino acid identity (Fig. 3). 
 
3.4.2 L gene sequence 
 The L gene of AMPV/CO was 6173 nt long from the gene-start to gene-end 
(GenBank accession no. AY513746). This size of the AMPV/CO L gene was comparable 
to the sizes of all other published paramyxovirus L genes (Table 2). The gene-start signal 
for the L gene of AMPV/CO was found to be 5′-GGACCAAGU-3′ (mRNA-sense). It 
was different from the highly conserved gene-start signal (5′-GGGACAAGU-3′) of all 
other genes of AMPV/CO (Yunus et al., 2003) and also from the L gene-start signal (5′-
AGGACCAAU-3′) of AMPV-A (Randhawa et al., 1996). The gene-end sequence of the 
L gene of AMPV/CO was 5′-UAGUUAUUUAAAAA-3′ (mRNA-sense), and showed 
resemblance to the gene-end signal of HMPV (5′-UAGUUAAUUAAAA-3′) and AMPV-
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A (5′-UAGUUAUAAAAA-3′) L genes. However, it was different from the gene-end 
sequences of other genes of AMPV/CO (Yunus et al., 2003).  
  
The longest ORF of the AMPV/CO L gene encoded a polypeptide of 2005 aa. 
The size of the L protein of AMPV/CO was exactly the same size as the L protein (2005 
aa) of HMPV (van den Hoogen et al., 2002), but one amino acid longer than the L protein 
of AMPV-A (Randhawa et al., 1996). The Mr of the AMPV/CO L protein was 
228,986 Da. The predicted AMPV/CO L protein was basic, with a net charge of +52 at 
neutral pH, and had a high leucine (11%) and isoleucine (6%) content.  
 
Alignment of the L protein sequences of AMPV/CO, HMPV and AMPV-A 
revealed that the L protein of AMPV/CO showed an 80% amino acid identity with the L 
protein of HMPV; whereas, the amino acid identity between the L proteins of AMPV/CO 
and AMPV-A was only 64% (Table 2). The L protein of AMPV/CO showed a lower 
percentage (46–47%) of amino acid identity with other known pneumovirus L proteins. 
The resemblance of AMPV/CO L protein to those of subfamily Paramyxovirinae ranged 
only between 13 and 15%. We performed a phylogenetic analysis of the predicted amino 
acid sequences of all twelve L proteins to determine the relationship between AMPV/CO 
and other paramyxoviruses (Fig. 4). Our results showed that AMPV/CO was 










Table 2. Comparison of the L gene and predicted L protein of AMPV/CO with those of 
other paramyxoviruses 
  




% nt similarity 
 















































a - Complete sequence not available 
b - Alignment based on partially published sequence (1111-1416 nt) 
c - Other viruses included human parainfluenza virus types 2 and 3, La Sota strain of 
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Figure 4. Phylogenetic analysis of the L ORFs of AMPV/CO and other paramyxoviruses. 
The putative L ORF of AMPV/CO was aligned with those of other paramyxoviruses and 
a phylogenetic tree was generated using the DNASTAR software program. The lengths 
of each pair of branches (obtained from ClustalW alignment – www.ebi.ac.uk/clustalw) 
are proportional to the amount of inferred evolutionary change, while the units at the 
bottom of the tree denote the number of substitution events. HRSV-A and HRSV-B, 
human respiratory syncytial virus types A and B; BRSV, bovine respiratory syncytial 
virus; HPIV-2 and HPIV-3, human parainfluenza virus types 2 and 3; NDV, La Sota 






Sequence analysis of the polymerase proteins of various non-segmented negative-
strand RNA viruses denoted that there are six conserved domains (I-VI) along the length 
of the protein, and the function of the L protein probably depends on these distinct 
domains (Poch et al., 1990 and Sidhu et al., 1993). All the six domains were also noticed 
in the AMPV/CO L protein as observed in the case of the AMPV-A L protein. The 
alignment of the four core polymerase motifs of domain III of 12 different paramyxovirus 
L proteins is shown in Fig. 5. Motifs A and C were perfectly conserved, while the motif 
B was nearly 100% conserved in the L proteins of the three metapneumoviruses. The D 
motif of the AMPV/CO L protein showed 70% and 90% identity with the corresponding 
motifs of AMPV-A and HMPV, respectively. The GDN tripeptide, which is similar to the 
catalytic GDD domain of positive-strand RNA virus RNA polymerases (Jablonski et al., 
1991), was conserved in all twelve L proteins analyzed in this study. 
 
The presence of an invariant tripeptide GHP in domain I was reported in the L 
proteins of AMPV-A (aa 365-367) and BRSV (aa 427-429) (Randhawa et al., 1996 and 
Yunus et al., 1998). A similar tripeptide was also observed at location 365-367 in the L 
protein of AMPV/CO. A stretch of hydrophobic residues (KERE), as observed in the 
BRSV L protein (aa 616-619), was also observed in the L protein of AMPV/CO (aa 554-
557). A putative nucleotide-binding motif was reported to lie within domain VI of many 
negative-stranded non-segmented RNA viruses (Poch et al., 1990; Randhawa et al., 1996; 
Yunus et al., 1998; Harcourt et al., 2001 and van den Hoogen et al., 2002). An ATP-
binding motif (aa 1673-1721) was also found in the L protein of AMPV/CO, but the 
number of the intermediate residues varied by one. 
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           A                                                        701 
AMPV/CO NNYIARASIVTDLSKFNQAFRYETSSVCADVVDELHGTQSLFCWLHLTVPLTTMICTYRHAPPETEG-VYDIDKIKEQS  
HMPV    ........................TAI....A...............I..M.....A........K.-E......E...  
AMPV-A  ........................T......A.................SS............D.G.-I....Q.P...  
HRSV-A  ....SKC..I...............CI.S..L.....V....F....AI.HV.I.........YIRDHIV.LNNVD...  
HRSV-B  ....SKC..I...............CI.S..L.....V....S.....I..V.I.........FIKDH.VNLNEVD...  
BRSV    ....SKC..I...............CI.S..L.....V....S.....I.FA.V.........YIRNHIT.LN.VD... 
HPIV-2  TFELSACF.T...A.YCLQW..Q.IIHF.RTLNRMY.VPH..E.I..RLIRS.LYVGDPFN..AATD-AF.L..VLNGD  
NDV     .RRRVATF.T...Q.YCLNW..Q.IKLF.HAINQ.M.LPHF.E.I..RLMD...FVGDPFN..SDPT-DC.LSRVPNDD 
HPIV-3  GYETVSCFLT...K.YCLNW...STALFGETCNQIF.LNK..N...PRLEGS.IYVGDPYC..SDKE-HISLEDHPDSG 
Sendai  GYETLSCFLT...K.YCLNW.F.STALFGQRCN.IF.FKTF.N.M.PVLEKC.IYVGDPYC.VADRM-HRQLQDHADSG 
Measles AYETVS.F.T...K.YCLNW....I.LF.QRLN.IY.LP.F.Q...KRLETSVLYVSDP.C..DLDA-HIPLY.VPNDQ 
Nipah   KFDTVS.FLT...K..CLNW...SMAIF.ERL..IY.LPGF.N.M.KRLERSVIYVADPNC..NIDK-HMELE.TPEDD   
                                                                         
 
                    B                             C            
                                                                                    779 
AMPV/CO GLYRFHMGGIEGWCQKLWTMEAISLLDVVSVKNRVQLTSLLNGDNQSIDVSKPVRLSQG-VDEVKADYSLAVKMLKEIR  
HMPV    ....Y...........................T.C.M.................K..E.-L..................  
AMPV-A  ................M..............R........................TGA-QT.IQ......I...TAV.  
HRSV-A  ....Y..............I.......LI.L.GKFSI.A.I........I......ME.-QTHAQ...L..LNS..LLY  
HRSV-B  ....Y..............I.......LI.L.GKFSI.A.I........I......IE.-QTHAQ...L..LNS..LLY  
BRSV    ....Y..............I.......LI.I.GKFSI.A.I........I...IK.NE.-QTHAQ...L..L.S..LLY  
HPIV-2  IFIVSK-.....L...M...IS..VIILS.AESKTRVM.MVQ....A.A.TTR.PR.LPSIQKKELA.AASKLFFERL.  
NDV     IYIVSAR.....L.......IS.AAIQLAAARSHCRVACMVQ....V.A.TRE..SDDSPEMVLTQLHQASDNFF..LI  
HPIV-3  FYVHNPR.....F......LIS..AIHLAA.RIG.RV.AMVQ....A.A.TTR.PNNYDYRIKKEIV.KDV.RFFDSL.  
Sendai  IFIHNPR.....Y......LIS..AIHLAA.RVG.RVSAMVQ....A.A.TSR.PVA.TYKQKKNHV.EEITRYFGAL.  
Measles IFIKYP......Y......IST.PY.YLAAYESG.RIA..VQ....T.A.T.R.PSTWPYNLKKREAARVTRDYFVIL.  
Nipah   IFIHYPK.....YS..T..IAT.PF.FLSAYETNTRIAAIVQ...E..AITQK.HPNLPYKVKKEICAKQ.QLYFERL.  
  
 
                 D 
                                                        829 
AMPV/CO  NAYKDIGHKLKEGETYISRDLQFMSKVIQSEGVMHPSPIKKILRVGPWIN  
HMPV     D..RN..................I............T............. 
AMPV-A   D..YN...........V.........T.......Y.AA...V........  
HRSV-A   KE.AG......GT.......M.....T..HN..YY.AS...V........ 
HRSV-B   KE.AG......GT.......M.....T..HN..YY.AS...V........ 
BRSV     KE.AS......GT.......M.....T..HN..YY.AS...V........ 
HPIV-2   ANNYGL..Q..AQ..I..STFFIY..RVFYQ.RILTQAL.NASKLCLTAD  
NDV      HVNHL...N..DR..IR.DTFFIY..R.FKD.AILSQVL.NSSKLVLVSG  
HPIV-3   EVMD.L..E..LN..I..SKMFIY..R.YYD.RIL.QAL.ALS.CVF.SE  
Sendai   HVMF....E..LN..I..SKMFVY..R.YYD.KIL.QCL.ALT.CVF.SE  
Measles  QRLH....H..AN..IV.SHFFVY..G.YYD.LLVSQSL.S.A.CVF.SE  
Nipah    MNLRAL..N..AT..I..TH.FIY..K.HYD.AVLSQAL.SMS.CCF.SE  
 
 
Figure 5. Amino acid sequence comparison of the putative polymerase core motifs (A, B, 
C and D) of domain III of the AMPV/CO L protein with those of other paramyxoviruses. 
All four motifs are boxed. Gaps are represented by dashes and perfectly-conserved amino 
acids relative to AMPV/CO are indicated by dots. HRSV-A and HRSV-B, human 
respiratory syncytial virus types A and B; BRSV, bovine respiratory syncytial virus; 
HPIV-2 and HPIV-3, human parainfluenza virus types 2 and 3; and NDV, La Sota strain 




3.4.3 Genomic termini sequences 
The 3′ leader of AMPV/CO was 40 nt long, and was comparable in length to 
those of AMPV-A (41 nt) and HMPV isolates CAN97-83 (41 nt), CAN98-75 (40 nt) and 
NL/1/99 (40 nt). The AMPV/CO leader region showed greatest similarity, both in length 
and nt identity, to those of CAN98-75 and NL/1/99. The 3′ leaders of all three viruses 
were 40 nt in length and exhibited 85% nucleotide identity among them. The first 17 nt of 
the leader regions of AMPV/CO and AMPV-A were also identical (Fig. 6).  
 
The 5′ trailer region of AMPV/CO was 39 nt long and was very similar to that of 
AMPV-A (40 nt), but relatively shorter when compared to the HMPV trailers (96 nt in 
CAN97-83 and 68 nt in CAN98-75). However, the extreme 18 nt at the 5′ end of both the 
Canadian isolates of HMPV were identical to that of AMPV/CO (Fig. 7). We observed 
that both the leader and trailer regions of AMPV/CO showed higher degrees of 
resemblance to those of HMPV than to those of AMPV-A, the only AMPV whose 
complete genomic sequence is available. This is in agreement with the observation that 
the other genes of AMPV/CO are also more similar to those of HMPV than to those of 
other AMPV subgroups. The leader and trailer regions of AMPV/CO were also highly 
complementary to each other; 11 of the first 13 nt and 18 of the terminal 30 nt were exact 
complements (Fig. 8). This high degree of conservation suggests that these residues 









      10        20        30        40   N Gene 
AMPV/CO  : 3’ UGCUCUUUUUUUGCGUAUAUUCUGUUGAAGGUUUGUUUUG-CCCUGUUCA  
AMPV-A   : 3’ .................AG...GUCCA.GAUC..U..A.UACCCUGUUCA  
CAN97-83 : 3’ ...G...........C.....UAA..C..U....U...GUACCCUGUUCA  
CAN98-75 : 3’ ...G...........C.....UAA..U.............-CCCUGUUUA 
NL/1/99  : 3’ ...G...........C.....UAA..U.............-CCCUGUUUA
HMPV 00-1: 3’ ...G...........C.....UAA.CU.......U...AUACCCUGUUCA  
 
 
Figure 6. Comparative alignment of the sequences (genomic-sense) of the 3′ leader 
regions of metapneumoviruses (AMPV/CO, AMPV-A and HMPV isolates 00-1, CAN97-
83, CAN98-75 and NL/1/99). Perfectly conserved nucleotides relative to AMPV/CO are 




                      10        20        30 
AMPV/CO  : 5’ ACGGCAAAAAAACCGUAUUCAUCCAAUUUUAGUUCCUCA- 
AMPV-A   : 5’ ...AG..................A.A....UAGCUU.U.G            
CAN97-83 : 5’ ..................A...U.....A..A..U..U.U 
CAN98-75 : 5’ ..................A...U......C.A..U..U.U 
NL/1/99  : 5’ ..................A...U......C.A..U..U.U 
HMPV 00-1: 5’ ..................A...U.....A..A..U..U.U 
 
 
Figure 7. Comparative alignment of the sequences (genomic-sense) of the 5′ trailer 
regions of metapneumoviruses (AMPV/CO, AMPV-A and HMPV isolates 00-1, CAN97-
83, CAN98-75 and NL/1/99). Perfectly conserved nucleotides relative to AMPV/CO are 






                      10        20        30        40 
AMPV/CO le: 3’ UGCUCUUUUUUUGCGUAUAUUCUGUUGAAGGUUUGUUUUG 
               ***  ********     * *  *** **     *   *                 




Figure 8. Complementarity between the genomic termini of AMPV/CO. The 






3.5.1 G gene 
 The complete G gene of AMPV/CO was 1798 nt long, encoding a predicted 
polypeptide of 585 aa (GenBank accession no. AY590691). The length of the G gene 
determined by us was 1015 nt longer than previously reported (Toquin et al., 2003). The 
G gene of AMPV/CO was significantly longer than those known for other MPVs. It was 
538–613 nt longer than the G genes of other AMPV subgroups and 1066–1087 nt longer 
those of HMPV. It is of interest to note that, although AMPV/CO showed genetic 
relatedness to HMPV with respect to most of its genes (van den Hoogen et al., 2002 and 
Govindarajan and Samal, 2004); it differed greatly from HMPV with respect to the length 
and sequence of the G gene. Determination of the G gene sequences of AMPV-C strains 
Mn-1a and Mn-2a revealed that the lengths and sequences of the G genes were conserved 
among strains of AMPV-C. Apart from the major ORF (ORF1), four potential secondary 
ORFs (ORF2, 146–1771 nt, 541 aa; ORF3, 155–1771 nt, 538 aa; ORF4, 167–1771 nt, 
534 aa; and ORF5, 1312–1608 nt, 98 aa) were also observed in the G gene of AMPV/CO, 
Mn-1a and Mn-2a. The predicted polypeptides from ORFs 2, 3 and 4 were in frame in the 
predicted polypeptide from the major ORF1. They resemble secreted forms of G protein 
as observed by their hydropathy analysis. However, it would be interesting to determine 
whether these secondary ORFs yield additional protein products or secreted forms of the 




The G protein of AMPV/CO showed only 21-25 % amino acid identity to the G 
proteins of HMPVs. However, the levels of amino acid identity to the G proteins of other 
AMPV subgroups were still lower: ranging from 14-16 %. This is in agreement with the 
general observation that the glycoproteins show low levels of identities. Among the US 
strains, the G protein of AMPV/CO showed 98 and 81 % amino acid identity to those of 
Mn-1a and Mn-2a, respectively. The predicted G proteins of Mn-1a and Mn-2a exhibited 
79 % amino acid identity between themselves. Our study also revealed that there is 
considerable variation in the G protein among the US strains of AMPV and a 
hypervariable region with only 48 % amino acid identity was observed between aa 300-
450 of the Mn-2a G protein. 
 
Careful examination of the nucleotide sequence of the G gene of AMPV/CO 
published by Alvarez et al. (2003) revealed that it contained partial sequences of the SH 
and G genes as a single G ORF. Our results also showed that all 783 nt of the G gene 
described by Toquin et al. (2003) were contained in the G gene sequence determined by 
us, but an additional 1015 nt insertion was identified between nt 752 and 753 of the G 
gene. These additional 1015 nt contained a higher G+C content (73 mol%) than the rest of 
the G gene (61 mol%). We believe that these 1015 nt probably contributed to the 
structural complexity in the genome that prevented successful and complete RT-PCR of 
the genomic RNA in vitro. In our study, the use of the smaller-sized G mRNA (compared 
with that of the genomic RNA), the direction of the RT reaction and the use of GC buffer 
II (TaKaRa) were probably responsible for our ability to amplify the secondary structure 
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region of the G gene successfully. This method will be useful in sequencing the G genes 
of other AMPV-C isolates.  
 
3.5.2 L gene 
 The L gene of AMPV/CO was 6173 nt long from gene-start to gene-end 
(GenBank accession no. AY513746). The longest ORF encoded a polypeptide of 2005 
aa. The size of the L protein of AMPV/CO was exactly the same size of the L protein 
(2005 aa) of HMPV (van den Hoogen et al., 2002), but one amino acid longer than the L 
protein of AMPV-A (Randhawa et al., 1996). Alignment of the predicted L protein 
sequence of AMPV/CO with that of HMPV revealed an 80% amino acid identity; 
whereas, the amino acid identity between the L proteins of AMPV/CO and AMPV-A was 
only 64%. A similar trend was also observed with the small hydrophobic protein (Yunus 
et al., 2003), the envelope glycoprotein (Govindarajan and Samal, 2004), and other 
proteins of AMPV/CO and HMPV (Govindarajan and Samal, 2005). The L protein of 
AMPV/CO showed a lower percentage (46–47%) of amino acid identity with other 
known pneumovirus L proteins and a much lower (13-15%) identity with the L proteins 
of the heterologous Paramyxovirinae subfamily. The L protein of HMPV also showed 
only 13–15% amino acid identity to those of Paramyxovirinae subfamily  (van den 
Hoogen et al., 2002). To our knowledge, this is the highest observed amino acid identity 
between the polymerase proteins of two viruses (whose sequences are available) within 
the genus Metapneumovirus that affect different host species. A higher amino acid 
identity (83.8%) was also observed between the BRSV L protein and HRSV L protein 
(Yunus et al., 1998). It is very surprising that an avian metapneumovirus more resembles 
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a human metapneumovirus than its avian counterparts. This indicates that there could be 
a possible evolutionary significance linked to this resemblance. However, these 
speculations and hypotheses need further studies and stronger evidence. 
 
3.5.3 Genomic termini 
The 3' leader region of AMPV/CO was 40 nt in length, and was comparable to the 
leader regions of AMPV-A (41 nt) and the HMPVs (40-41 nt). The leader region of 
AMPV/CO also showed higher levels of sequence similarity to the isolates of HMPV. 
However, the first 17 nt of the leader regions of AMPV/CO and AMPV-A were also 
identical. The 5' trailer region of AMPV/CO was 39 nt long and was very similar to that 
of AMPV-A (40 nt), but relatively shorter when compared to the HMPV trailers (96 nt in 
CAN97-83 and 68 nt in CAN98-75). We also observed that trailer region of AMPV/CO 
showed higher degree of resemblance to that of HMPV than to the trailer region of 
AMPV-A. This is in agreement with the observation that the other genes of AMPV/CO 
are also more similar to those of HMPV than to those of other AMPV subgroups. The 
leader and trailer regions of AMPV/CO were also highly complementary to each other; 
11 of the first 13 nt and 18 of the terminal 30 nt were exact complements, indicating that 
these residues might probably be part of the genomic and antigenomic promoters.     
 
3.5.4 Complete genome 
Determination of the nucleotide sequence of the G gene, L gene and the genomic termini, 
together with the published sequences of other genes and intergenic regions, enabled us 






found that AMPV/CO genome was 14,150 nt long (Fig. 9) and, thus possesses the longest 
genome among metapneumoviruses whose complete genomic data are currently available 
(Govindarajan and Samal, 2005). These results contradict the recent findings that the 
AMPV/CO full-length genome was 13,134 nt long and was the smallest of all 
pneumoviruses (Lwamba et al., 2004). Comparison of our sequence data with the recent 
findings revealed that the AMPV/CO genome was longer due to the longer G gene. The 
complete genome of AMPV/CO showed a structural organization similar to that of 
AMPV-A and HMPV, and all the genes except the G gene were comparable in size to the 
corresponding genes in AMPV-A or HMPV (Randhawa et al., 1997 and Biacchesi et al., 
2003). As observed in other pneumoviruses, AMPV/CO did not seem to follow the “rule 
of six”, since the complete genome length was not a multiple of six (Randhawa et al., 
1997; Biacchesi et al., 2003 and Samal and Collins, 1996). 
  
The putative gene-start, gene-end and intergenic sequences of AMPV/CO are 
presented in Fig. 10. The gene-start signal 5′ GGGACAAGU 3′ (mRNA-sense) was 
highly-conserved in all the genes of AMPV/CO except the L gene, which had a slightly 
different gene-start signal, 5′ GGACCAAGU 3′. The consensus gene-start signal for 
AMPV/CO genome was 5′ GGGACAAGUnAAnAUG 3′, the AUG being the first 
initiation codon for the gene. The consensus gene-end signal for AMPV/CO was 5′ 
UAGUUAnUnAAAAA 3′ (Fig. 10), very similar to that of HMPV (Biacchesi et al., 
2003), and showed resemblance to that of AMPV-A (Ling et al., 1992). The intergenic 
regions of AMPV/CO varied in length (1-91 nt) and did not show any discernible 
conserved features. The SH-G intergenic region of AMPV/CO was the longest, 
Figure 9. Structure of AMPV/CO genome. Individual genes are indicated by boxes. The gene length and protein length are indicated 






                                                          1              LEADER (40nt)              40 
                     5’ acgagaaaaaaacgcatataagacaacttccaaacaaaac  
                                   
       gene end   intergenic    gene start   
                                     4            1                   
                                                            GGGACAAGTgAA-AATGtctct  N 
 
                        1246                                  1248 
      N  ttatgAGTaAtTaAAAAA-     c                          GGGACAAGTcAA-AATGtcctt  P 
 
                                                  2158           2156  
      P  tatgTAGTTAaTaAAAAA-     c                          GGGACAAGTggA-AATGgagtc  M 
 
                                                      3028       3025  
      M  gataTtaTTtagaAAAAA-     tt                         GGGACAAGTgAA-AATGtcttg  F 
 
                                                  4674           4671  
      F  atttTAGTTAcTaAAAAA-     tt                         GGGACAAGTgAA-gATGtctcg  M2 
 
                                              5424             5421   
      M2 ttctaAGTTAaTaAAAAAA     tt                         GGGACAAGTcAA-cATGgagcc  SH 
 
                                                6138             6046  
     SH ttttTAGTTAtTtAAAAA-     tcatg – 81 nt – aaaac      GGGACAAGTcAA-cATGgaggt  G  
 
                                                  7939           7935  
     G  aagtTAGTTAaTtAAAAA-     gaa                        GGacCAAGTtAAaAATGgatcc  L  
 
                          14111 
      L  caatTAGTTAtTtAAAAA  
 
Consensus    TAGTTAnTnAAAAA                                 GGGACAAGTnAAnATG 
 
                       14112            TRAILER (39 nt)         14150 
                        tgaggaactaaaattggatgaatacggtttttttgccgt 3’    
 
 
Figure 10. Complete gene map of AMPV/CO genome (in antigenome-sense). The last 
nucleotide of the gene-end, the first nucleotide of the gene-start, and the first and last 
nucleotides of the leader and trailer are numbered. Conserved sequence motifs at the 
gene-end and the gene-start of each gene are indicated in bold upper case, and a 
consensus is given below. Translational stop and start codons are underlined. Intergenic 
sequences are shown between the gene-end and gene-start sequences. In the SH-G 
intergenic region (91 nucleotides), only the first and last five nucleotides are shown, and 
the number of the remaining nucleotides is indicated.  
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comprising 91 nt, while the other intergenic regions ranged from 1 to 3 nt in length. The 
SH-G and the G-L intergenic regions were longer than the other intergenic regions in the 
Canadian isolates of HMPV (Biacchesi et al., 2003). The G-L intergenic region of 
AMPV-A was 69 nt long (Randhawa et al., 1996), while only 3 nt long in AMPV/CO. 
These observations denote that there is no discernible pattern in the nucleotide 
arrangement in the intergenic regions among the metapneumoviruses.  
 
With the completion of the entire genomic sequence of AMPV/CO, we were able to 
compare the aa identity of each protein of AMPV/CO with the corresponding proteins of 
other MPVs. All the eight proteins of AMPV/CO invariably showed higher levels of aa 
identity with the corresponding proteins of HMPVs than with those of the AMPVs of 
subgroups A, B and D (Table 3). The N and M proteins of AMPV/CO showed the 
greatest identity (86-88%) with those of the HMPVs. The M2, F and L proteins of 
AMPV/CO also showed greater than 80 % aa identity with the corresponding proteins of 
the HMPVs. Among the membrane-associated glycoproteins, the F protein, rather than 
SH or G, of AMPV/CO showed greater aa identity with that of the HMPVs. These 
observations that AMPV/CO more closely resembles HMPV than other AMPVs are 
surprising and require further study with respect to virus evolution or cross-infectivity. 
Data on the complete genome is essential for the development of a reverse genetics 
system for AMPV/CO. Recovery of infectious AMPV-C from cDNA will be of great use 
in studying the molecular biology of this virus or other closely related human pathogens, 







Table 3. Percent amino acid identity between the putative ORFs of AMPV/CO and those 




















































































a – sequence not available 
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Chapter 4: Construction of full-length cDNA clones and 
recovery of infectious AMPV/COs entirely from cDNA 
 
4.1 Abstract 
 A full-length cDNA clone of AMPV/CO represented in 5 subgenomic 
cDNA fragments was assembled in a transcription plasmid based on pBR 322, between 
the T7 RNA polymerase promoter and the autocatalytic hepatitis delta virus ribozyme. 
Transfection of this plasmid into BSR-T7 cells that stably express the T7 RNA 
polymerase resulted in the synthesis of antigenomic AMPV/CO RNA. Simultaneous 
transfection of T7 promoter-driven plasmids expressing AMPV/CO N, P, M2-1 and L 
proteins resulted in replication and transcription of the generated antigenomic RNA. 
Recombinant virus was then amplified and recovered after further passage in susceptible 
Vero cells. The authenticity of the recovered recombinant virus was confirmed by the 
presence of the artificially-introduced restriction site markers. The recombinant 
AMPV/CO showed similar growth characteristics in tissue culture to that of the parental 
virus. These results demonstrate that it is possible to generate genetically engineered 
AMPV/CO by manipulating the viral genome at the DNA level through reverse genetic 
techniques. A recombinant virus rAMPV/CO-GFP expressing green fluorescent protein 
(GFP) as a foreign protein was also generated by similar techniques. The GFP-expressing 
recombinant virus grew to one-log lower titer than the wild-type virus but stably 
expressed GFP for at least five serial passages in Vero cells. These results indicate that 
using the newly established reverse genetic system AMPV/CO can be engineered to 




 Avian metapneumovirus (AMPV) causes an acute respiratory disease in turkeys 
and is associated with swollen head syndrome in chickens. The virus also affects many 
other species of birds. AMPV is a member of the genus Metapneumovirus in the 
subfamily Pneumovirinae of the family Paramyxoviridae (Pringle, 1998). The genus 
Metapneumovirus contains the AMPV and its mammalian counterpart, the human 
metapneumovirus (HMPV). HMPV causes respiratory tract disease, especially in young 
children (van den Hoogen et al., 2001). Based on nucleotide sequence divergence in the 
attachment glycoprotein genes and their antigenic differences, AMPVs have been 
classified into four subgroups – AMPV-A, AMPV-B, AMPV-C and AMPV-D (Juhasz 
and Easton, 1994; Eterradossi et al., 1995 and Bäyon-Auboyer et al., 1999). The US 
isolates of AMPV belong to subgroup C, and exhibit genetic and antigenic differences 
from isolates of other subgroups (Seal, 1998; Cook et al., 1999 and Toquin et al., 2000). 
Interestingly, several reports have shown that AMPV-C shows a closer resemblance to 
HMPV than to other AMPV subgroups (van den Hoogen et al., 2002; Yunus et al., 2003; 
Toquin et al., 2003; Govindarajan and Samal, 2004, Govindarajan et al., 2004 and 
Govindarajan and Samal, 2005).  
 
AMPV was first isolated in the US in 1996 in Colorado from commercial turkeys 
with rhinotracheitis (Kleven, 1997 and Cook et al., 1999). Subsequently, AMPV 
outbreaks were reported in Minnesota, from where it has spread to neighboring states. 
The disease has emerged as a major economic problem for turkey farmers, causing 
economic losses of approximately $15 million annually. The mortality due to AMPV 
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infection and concomitant secondary bacterial infections ranges 0–30% in the US 
(Alvarez et al., 2003). Currently, killed or live-attenuated vaccines are being used to 
control this emerging pathogen (Goyal and Sheikh, 1999; Patnayak et al., 2002; Patnayak 
et al., 2003 and Patnayak and Goyal, 2004). However, the main disadvantage of the 
currently-available live attenuated AMPV vaccines is that they can themselves cause the 
disease leading to morbidity and mortality in vaccinated birds. Thus, development of a 
completely non-pathogenic AMPV vaccine would be highly beneficial to the turkey 
industry. 
 
At present, there is no appropriate method to genetically engineer attenuated 
AMPV strains. Genetic manipulation of the virus would be needed to design an effective 
vaccine candidate, which is both safe and highly efficacious. Genetic manipulation of 
DNA viruses and positive-stranded RNA viruses has been established for quite some 
time. In recent years, it has been possible to genetically manipulate the genome of 
negative-sense RNA viruses due to the development of reverse genetic systems (reviewed 
in Collins and Murphy, 2002, Neumann et al., 2002 and Conzelmann, 1998). 
 
AMPV contains a non-segmented negative-stranded RNA genome which is 
14,150 nucleotides long (Govindarajan and Samal, 2005). The genome contains eight 
genes, which encode the nucleocapsid protein (N), phosphoprotein (P), matrix protein 
(M), fusion protein (F), second matrix proteins (M2-1 and M2-2), small hydrophobic 
protein (SH), attachment glycoprotein (G) and the large polymerase protein (L). As 
encountered in other non-segmented negative-sense RNA viruses, the genomic RNA of 
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AMPV is not infectious by itself. Other components of the ribonucleoprotein complex 
(N, P and L proteins) are essential to initiate virus-specific mRNA synthesis and thus the 
production of infectious virus. Due to recent technological advances, by co-transfecting 
plasmids expressing the full-length antigenomic viral RNA and the support plasmids (N, 
P, and L proteins), all under the control of T7 promoter, it is possible to recover 
infectious virus entirely from cloned cDNA. The source of the T7 RNA polymerase 
usually used for virus recovery is either a recombinant vaccinia virus expressing T7 RNA 
polymerase or a cell line that constitutively expresses the T7 RNA polymerase. Using this 
approach, numerous non-segmented negative-sense RNA viruses have been recovered 
(rabies virus, Schnell et al., 1994; vesicular stomatitis virus, Lawson et al., 1995; human 
respiratory syncytial virus, Collins et al., 1995; measles virus, Radecke et al., 1995; 
Sendai virus, Garcin et al., 1995; SV5, He et al., 1997; rinderpest virus, Baron and 
Barrett, 1997; parainfluenza virus, Hoffman and Banerjee, 1997; bovine respiratory 
syncytial virus, Buchholz et al., 1999 and Yunus et al., 2001; Newcastle disease virus, 
Peeters et al., 1999 and Krishnamurthy et al., 2000; human metapneumovirus, Biacchesi 
et al., 2004 and Herfst et al., 2004; and AMPV-A, Naylor et al., 2004). 
 
In this chapter, we describe the recovery of AMPV-C strain Colorado 
(AMPV/CO) entirely from cloned cDNA using reverse genetic techniques. The recovered 
recombinant virus was biologically and antigenically similar to the parental wild type 
virus. This newly established virus rescue system will provide important applications for 
the development of safe and efficacious attenuated vaccine strains. In addition, the 
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manipulation of the AMPV genome at the DNA level will be highly useful for further 
studies on AMPV virulence, pathogenesis and molecular biology.  
 
An important application of reverse genetics system is to engineer 
paramyxoviruses to express additional foreign proteins.  Studies over the last many years 
have indicated the genome of paramyxoviruses to be very elastic and that they can be 
manipulated to stably express foreign proteins. The reverse genetics system developed by 
us was used to generate a recombinant AMPV/CO that stably expresses GFP as a foreign 
gene i.e. study the potential of AMPV/CO as a virus vector. The foreign gene selected for 
this study was enhanced green fluorescent protein (GFP) so that it will enable us to study 
both the rescue of the virus as well as its vector potential at the same time. The GFP-
expressing recombinant AMPV/CO was similar to the wild type virus except that there 
was a slight reduction in virus titer.  These results indicate that it is possible to engineer 
AMPV/CO to stably express foreign proteins through reverse genetic techniques. 
 
4.3 Materials and methods 
 
4.3.1 Cells and virus  
 Vero cells were maintained in MEM (Invitrogen GIBCO) supplemented with 10% 
fetal calf serum. Baby hamster kidney cells that constitutively express T7 RNA 
polymerase (BSR T7/5, Buchholz et al., 1999) were a generous gift from Dr. Karl-Klaus 
Conzelmann (Ludwig-Maximilians-University Munich, Munich, Germany). These cells 
were maintained in Glasgow MEM (Invitrogen GIBCO) supplemented with 10% fetal 
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calf serum, glutamine and amino acids under geneticin (1mg/ml) selection every second 
passage. AMPV-C strain Colorado (AMPV/CO) was obtained from the National 
Veterinary Services Laboratory (Ames, IA, USA).  
 
4.3.2 Viral RNA extraction 
 AMPV/CO and the recombinant AMPV described below were grown in confluent 
monolayers of Vero cells supplemented with 2% fetal calf serum. The virus propagation, 
purification and RNA extraction were performed in a manner similar to those described 
elsewhere (Govindarajan and Samal, 2004). Briefly, Vero cells were infected with the 
parental AMPV/CO or the recombinant virus and incubated at 370 C for 72 h. Virus was 
harvested when maximum cytopathic effect was evident as extensive syncytia. The 
infected cells were scraped into the medium and lysed by three cycles of freezing and 
thawing to release the intracellular virus. The cell lysate was clarified at 3000 g for 
15 min, and the supernatant was made 10% with respect to PEG 8000 (Sigma) and 
incubated for 3 h at 4 °C. Subsequently, the virus was pelleted at 4000 g for 30 min at 
4 °C. Viral genomic RNA was extracted from the viral pellet using TRIzol reagent 
(Invitrogen) according to the manufacturer’s protocol, except an additional extraction 
with phenol plus chloroform. 
 
4.3.3 Construction of expression plasmids 
 cDNA fragments bearing the ORFs of N, P, M2-1 and L genes were generated by 
RT-PCR. All RT reactions were performed with Superscript II reverse transcriptase 
(Invitrogen) and gene specific primers. The primers used in the RT-PCR reactions are 
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listed in Table 4. The expression plasmid pTM-1 that possesses the encephalomyocarditis 
virus internal ribosome entry site (IRES) downstream of the T7 RNA polymerase 
promoter and uses the translation initiation codon contained in the Nco I site of the IRES 
was used to clone the N, P, M2-1 and L ORFs. The N, P and M2-1 ORFs were cloned 
individually in pTM-1 between Nco I and BamH I sites. The L gene ORF was cloned 
between the Nco I and Xho I sites by a two-step cloning procedure using the Xma I site 
as the third restriction site. The Xma I site was introduced in the L gene ORF without any 
alteration of amino acid sequence by changing 2 nt (nt 9656 A→C and nt 9659 A→G). 
The N, P, M2-1 and L ORFs in pTM-1, designated as pN, pP, pM2-1 and pL 
respectively, were sequenced to their entirety using an ABI 3100 DNA sequencer 
(Applied Biosystems).  
 
4.3.4 Construction of full-length plasmid 
 Restriction map analysis of the complete genome of AMPV/CO was performed to 
decide the strategy to be used to clone the complete genome into the plasmid pBR322/dr. 
Plasmid pBR322/dr was a modified form of plasmid pBR322 which contained a 72-
nucleotide oligo linker between the EcoR I and Pst I sites and hepatitis delta viral 84-
nucleotide antigenome ribozyme sequence and T7 RNA polymerase transcription 
termination signal between the Rsr II and Fse I sties (Krishnamurthy et al., 2000). Based 
on the restriction profile of the complete genome of AMPV/CO, we decided to clone the 










Table 4. Oligonucleotide primers used for cDNA synthesis and RT-PCR of  




























































    
 
 
Figure 11. Generation of full-length AMPV/CO plasmid. Full-length AMPV/CO cDNA was assembled in pBR 322 from five 
subgenomic cDNA fragments that were generated by high-fidelity RT-PCR. The fragments were inserted in between the T7 RNA 
polymerase promoter sequence and the hepatitis delta ribozyme autocatalytic sequence which was followed by the T7 terminator 
sequence. The names of the restriction enzymes used for the assembly are shown at the top and the order in which the fragments were 
assembled is shown on each of them. The Xho I, Pvu I and Mlu I sites were introduced to facilitate construction and serve as markers 
(sequence changes shown in lower case and underlined).  
All RT reactions, excepting the G gene fragments, were carried out using 
Superscript II reverse transcriptase (Invitrogen). The primers used for RT-PCR of each 
fragment are listed in Table 5. The G gene cDNA fragment bearing the complete G gene, 
from gene-start to gene-end, flanked by Pvu I and Mlu I sites was generated as descried 
in section 3.3.2. Three restriction sites (Xho I, Pvu I and Mlu I) were artificially 
introduced during the cloning so as to help in cloning as well as to serve as markers to 
confirm the identity of the recovered recombinant virus. The Xho I site was introduced 
between the M and F genes, in the non-coding region after the M gene stop codon, by 
altering 3 nucleotides (nt 2988-2990). The Pvu I site was introduced in the SH-G 
intergenic region by altering one nucleotide (nt 6124). The Mlu I site was introduced 
between the G and L genes, in the non-coding region after the G gene termination codon, 
by altering 3 nucleotides (nt 7916, 7918 and 7919). None of the artificially introduced 
marker sites involved amino acid-coding sequences. The Age I restriction site (nt 12960) 
was a unique site already present on the genome, which was also included in the cloning 
process. 
 
The five fragments were cloned in the order given in Table 5. After ligation into 
the plasmid, each fragment was sequenced completely using an ABI 3100 DNA 
sequencer (Applied Biosystems). The resulting AMPV/CO full length expression plasmid 
was termed pAMPV/CO. This plasmid contained three non-viral G residues adjacent to 
the T7 promoter, at the 5' end of the antigenome, to enhance promoter efficiency 


















































































The cDNA fragments correspond to the fragments in Fig. 11. T7 promoter sequences are 
marked in italic type, the virus-specific sequences are underlined, and restriction sites are 
marked in bold type. The partial HDV ribozyme sequence (24-nt) overhang is shown in 







4.3.5 Construction of full-length plasmid encoding GFP 
 The antigenomic pAMPV/CO plasmid was modified by the insertion of a 
transcription cassette containing the ORF for enhanced GFP (Clontech, Inc.) (Fig. 12). 
The cassette was introduced as a single fragment at the Mlu I site created between the G 
and L genes, in the non-coding region after the G gene termination codon, by altering 
three nucleotides (nt 7916, 7918 and 7919). The transcription cassette contained the Mlu 
I recognition sequence followed by the 14-nt putative G gene-end sequence 
(TAGTTAATTAAAAA, positive sense, AMPV/CO nt 7922-7935), followed by a 2nt 
intergenic sequence (CC, positive sense), followed by the 16-nt putative N gene-start 
sequence (GGGACAAGTGAAAATG, positive sense, AMPV/CO nt 41-56, N ORF 
initiation codon italicized and underlined), followed by the GFP ORF, followed by the 
Mlu I recognition sequence. The fragment was digested with Mlu I and cloned into 
pAMPV/CO resulting in the final construct pAMPV/CO-GFP (Fig. 12). The length of the 
encoded rAMPV/CO-GFP antigenome, excluding the non-viral sequences, would be 
14,905 nt. 
 
4.3.6 Transfection and recovery of infectious recombinant AMPV/COs 
 Transfection experiments were performed in BSR T7/5 cells grown to 90-95% 
confluency in 6-well plates (Fig. 13). The medium was changed with Glasgow MEM, 
without serum, at least 1 h before transfection. The cells were then transfected with 5 µg 
each of the full-length plasmids (pAMPV/CO and pAMPV/CO-GFP), 2 µg each of pN 
and pP, 1 µg each of pM2-1 and pL plasmids in a volume of 100 µl of Opti MEM per 






Figure 12. Construction of plasmid pAMPV/CO-GFP expressing the complete antigenomic RNA of AMPV/CO and GFP as a foreign 
gene. GFP was inserted in the putative 5' non-coding region of the G gene as a separate transcription cassette. The cassette contained 
the GFP ORF (black rectangle) that was flanked on the upstream side by a Mlu I site (underlined), the G GE motif (italicized), an 
intergenic region comprised of two C residues, and the N GS motif (bold). The GFP ORF was flanked on the downstream side by a 
Mlu I site (underlined). 
Figure 13. Plasmid-based recovery of recombinant AMPV/CO. BHK cells stably expressing T7 RNA polymerase were cotransfected 
with the antigenome plasmid and four expression plasmids encoding N, P, M2-1 and L proteins of AMPV/CO. This schematic 
represents the events that occur in the transfected cells leading to the recovery of recombinant viral particles.  
 
 
the manufacturer’s directions. The transfection mixture was removed after 6 h of 
incubation at 370 C and the transfected cells were washed and maintained with Glasgow 
MEM containing 3% fetal bovine serum. Cells transfected with pAMPV/CO-GFP were 
monitored by fluorescent microscopy (Zeiss) for the expression of GFP. Three to four 
days after transfection, all the media was used for infecting a fresh batch of Vero cells in 
6-well plates or T-25 flasks and observed for the development of virus-induced 
cytopathic effect (CPE) and also expression of GFP (cells transfected with the GFP 
plasmid). After one additional passage, the supernatant was harvested and clarified for 
further purification of the recombinant virus.  
 
4.3.7 RT-PCR and demonstration of genetic markers 
 RT-PCR was performed on the RNA extracted from the recovered viruses to 
demonstrate the presence of the artificially introduced genetic markers. Briefly, the 
recombinant viruses were grown in Vero cells. Viral RNA was extracted using RNeasy 
Mini Kit (Qiagen) and RT-PCR was performed to demonstrate the presence of the Xho I, 
Pvu I and Mlu I markers that were artificially-introduced during the cloning process. We 
also performed RT-PCR to amplify the GFP gene from the recovered GFP-expressing 
recombinant AMPV/CO. The obtained RT-PCR products were then subjected to DNA 
sequencing to confirm the presence of the artificially-introduced markers. Control 
reactions without RT were included to show that the PCR products were derived from 




4.3.8 Virus growth 
 Multiple-step growth characteristics of the recombinant viruses were compared 
with those of the parental virus. Briefly, Vero cell monolayers grown in 6-well plates 
were infected with 0.01 MOI of the parental, rAMPV/CO and rAMPV/CO-GFP virus. 
Supernatants (0.2 ml) were collected at indicated time points post-infection and replaced 
by an equivalent volume of fresh medium. The collected samples were flash frozen, 
stored at -700 C, and titrated later in parallel by plaque assay. Each growth curve is based 
on the average of the virus titers from two infected monolayers. 
 
4.3.9 Antibody staining of plaques 
 The recovered recombinant viruses were grown in Vero cells maintained in MEM 
supplemented with 2% fetal bovine serum and 0.8% methyl cellulose (Sigma). After 
incubation for 4 days at 370 C, the overlay was removed and the monolayer was fixed 
with 4% paraformaldehyde solution. The cells were then permeabilized with 1:1 acetone 
in phosphate-buffered saline (PBS) at -200 C for 2 min. The plaques were then incubated 
with rabbit polyclonal antisera (1:1000 dilution) raised against a polypeptide 
(KDNSGPIPQNQRPSS, aa 140 to 154 on N ORF) of the predicted N protein of 
AMPV/CO (Spring Valley Laboratories, MD, USA), followed by incubation with goat 
anti-rabbit IgG tagged with horseradish peroxidase (KPL, MD, USA). The plaques were 




4.3.10 Plaque assay 
Plaque assays to measure the virus titers were performed on 24-well plates 
containing confluent Vero cells. The monolayer was incubated with 10-fold serial virus 
dilutions for 1h at 370 C. After virus adsorption, the inoculum was removed and replaced 
with 1 ml of OptiMEM containing 2 % fetal bovine serum and 0.8 % methyl cellulose 
(Sigma) and the cells were incubated at 370 C. After 4 days post infection, the methyl 
cellulose overlays were removed and the cells were fixed with 80 % methanol. The fixed 
monolayer was then blocked with 5 % (wt/vol) nonfat dry milk in PBS and the cells were 
incubated with rabbit polyclonal antipeptide antibody (1:1000 dilution) raised against the 
AMPV/CO N protein (Spring Valley Laboratories, MD, USA). The cells were then 
incubated with horseradish peroxidase-labeled goat anti-rabbit antibodies (KPL, MD, 
USA). Viral plaques were counted following incubation with DAB substrate chromogen 
(Sigma) to determine virus titers. For the GFP-expressing rAMPV/CO-GFP, the number 
of viral foci was counted by fluorescent microscopy and was also confirmed with the 




4.4.1 Construction of a plasmid encoding the full-length AMPV/CO genome 
A cDNA clone encoding the complete 14,150-nt antigenome of AMPV-C strain 
Colorado was constructed by sequential cloning of individual cDNA fragments, as 
depicted in Fig. 11. Five overlapping cDNA fragments were generated: fragment 1 
contained the putative N, P, and M genes, flanked by T7 RNA polymerase promoter at 
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the upstream end and an Xho I site at the downstream end. The Xho I site was created by 
three nucleotide substitutions in the putative non-coding region following the termination 
codon of the M gene and served as a genetic marker to distinguish between the 
recombinant and the wild-type parental virus. Fragment 2 contained the putative F, M2 
and SH genes and was flanked by the Xho I site at the upstream end and a Pvu I site at 
the downstream end. The Pvu I site was created by one nucleotide substitution in the 
putative SH-G intergenic region and also served as a genetic marker to distinguish 
between the recombinant and the wild-type parental virus. Fragment 3 contained the 
putative G gene and was bordered on the upstream end by the Pvu I site and on the 
downstream end by a Mlu I site that was created by three nucleotide substitutions in the 
putative non-coding region following the termination codon of the G gene. Fragment 4 
contained the upstream sequences of the putative L gene and was bordered on the 
upstream end by the Mlu I site and on the downstream end by a naturally occurring Age I 
site. Fragment 5 contained the remaining sequences of the putative L gene and the trailer 
sequence, flanked by the Age I site at the upstream end and part of the hepatitis delta 
virus ribozyme sequence ending in an Rsr II site at the downstream end. The Rsr II site is 
a naturally occurring restriction site in the hepatitis delta virus ribozyme. The low-copy 
number plasmid vector pBR322 supplied the remaining part of the hepatitis delta virus 
ribozyme followed by a T7 RNA polymerase terminator sequence. The full-length 
plasmid was named as pAMPV/CO. The resulting AMPV/CO cDNA in the plasmid 
pAMPV/CO was sequenced to its entirety. Sequence analysis revealed that pAMPV/CO 
was a faithful copy of the 14150-nt AMPV/CO genome except for the artificially 
introduced genetic markers at the Xho I, Pvu I and Mlu I sites.   
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4.4.2 Construction of full-length plasmid encoding GFP 
In order to assist in the recovery and identification of the cDNA-derived virus, the 
full-length plasmid pAMPV/CO was modified such that it contained a transcription 
cassette encoding GFP at the Mlu I site created between the G and L genes in the putative 
5' untranslated region. In addition to providing a means to monitor the recovery of 
rAMPV, this also helped in studying the potential of AMPV to serve as a viral vector. 
The procedure of cloning the GFP transcription cassette into the full-length plasmid 
pAMPV/CO is shown in Fig. 12. The foreign gene cassette consisted of appropriate viral 
GS and GE signals to enable proper transcription. The resulting plasmid, pAMPV/CO-
GFP, was sequenced at the flanking sites of the Mlu I cloning site to confirm the insertion 
of the foreign cassette.  
 
4.4.3 Recovery of infectious recombinant viruses 
 The antigenome plasmids pAMPV/CO and pAMPV/CO-GFP, along with a panel 
of the support plasmids encoding the N, P, M2-1 and L proteins, were transfected into 
BSR T7/5 cells that stably express the T7 RNA polymerase. In a parallel transfection, 
plasmid encoding the L protein was excluded to serve as a negative control. In the case of 
pAMPV/CO-GFP, the transfected cells were examined by fluorescent microscopy on 
successive days after transfection. Green cells were visualized by the day after 
transfection. Initially, they appeared as scattered isolated cells and subsequently they 
formed foci of more cells that later on developed into well-formed syncytia, similar to the 






rAMPV/CO-GFP was also possible without the inclusion of M2-1 protein in the 
transfection mixture.  
 
Three days after transfection, the cells were scraped into the medium, and the 
total suspension was transferred onto fresh Vero cells and observed for the appearance of 
CPE characteristic of AMPV/CO. Further passages were performed onto new Vero cells 
to amplify the recovered recombinant viruses (rAMPV/CO and rAMPV/CO-GFP).  RT-
PCR was performed on the RNA extracted from the recovered virus and the obtained 
products were then subjected to DNA sequencing to confirm the presence of the 
artificially introduced genetic tags (Figs. 14 and 15).  
 
4.4.4 Characteristics of the recovered rAMPV/COs 
 The recovered rAMPV/CO and rAMPV/CO-GFP viruses were compared to its 
parental wild-type AMPV/CO for their growth characteristics. Multiple-step growth cycle 
replication of rAMPV/CO, rAMPV/CO-GFP and wild-type AMPV/CO was evaluated 
following inoculation of Vero cells at an MOI of 0.01 (Fig. 16). Both the kinetics and 
magnitude of replication of rAMPV/CO were similar to those of the parental virus. Virus 
titers of wild-type AMPV/CO and rAMPV/CO in the supernatants collected at 72 h post-
inoculation were around 106.0 pfu/ml (Fig.16). On the other hand, the kinetics and 
magnitude of replication of the GFP-expressing rAMPV/CO-GFP were slightly lower 
than those of the wild-type AMPV/CO as well as rAMPV/CO. Virus titer of rAMPV/CO-
GFP at 72 h post-inoculation was around 105.3 pfu/ml (Fig.16).  
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Figure 14. Identification of genetic marker in the genome of rAMPV/CO. Primers spanning the M-F gene junction were utilized for 
RT-PCR and the obtained product was subjected to DNA sequence analysis. Wild type AMPV/CO was used as control. The 3 
nucleotides (TGA, underlined in wt AMPV/CO) were modified during cloning to accommodate an Xho I restriction site (CTC, 







1     2      3     4     5      6     7
















Figure 15. Confirmation of the presence of GFP gene in the genome of the recovered 
rAMPV/CO-GFP.  Specific primers spanning the M-F gene junction (lanes 3 and 6) and 
the G-L gene junction (lanes 4 and 7) were utilized for RT-PCR. The larger product 
(1311 bp, lane 7) from rAMPV/CO-GFP confirmed the presence of GFP gene compared 
to the smaller product (556 bp, lane 4) from wt AMPV/CO. Lane 1 – 1 Kb Plus marker; 
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Figure 16. Replication kinetics of wild-type AMPV/CO, rAMPV/CO and rAMPV/CO-
GFP. Vero cells were infected at a multiplicity of infection of 0.01 with wtAMPV/CO 
(♦), rAMPV/CO (■), or rAMPV/CO-GFP (▲). Supernatants (0.2 ml out of a total 
volume of 3 ml per well) were taken at the indicated time points post-inoculation and 
replaced by an equivalent amount of fresh medium. The samples were flash frozen and 
analyzed later for virus titers by plaque assay and immunostaining. Each time point was 
represented by two wells, and each titration was performed in duplicate. The mean virus 








Both rAMPV/CO and rAMPV/CO-GFP induced CPE, consisting of large 
syncytia, similar to that of the wild type virus in cultured Vero cells (Fig. 17). The 
syncytia induced by both viruses were similar and were indistinguishable. The maximal 
CPE in Vero cells infected with either virus was observed after 72 h of infection. 
Furthermore, the recovered viruses were compared with the wild-type AMPV/CO for 
their antigenic characteristics in an immunoperoxidase plaque-staining reaction (Fig. 18). 
We observed that the plaques induced by either virus were similar in size and 
morphology and thus indistinguishable.  
 
4.5 Discussion 
In this study, we report the recovery of infectious AMPV-C strain Colorado 
(rAMPV/CO and rAMPV/CO-GFP) entirely from cloned cDNA. The complete genome 
data available for AMPV/CO (Govindarajan and Samal, 2005) was used to generate a 
reverse genetics system for this emerging turkey pathogen. A vaccinia virus-free recovery 
system comprising a T7-expressing cell line was used for virus recovery (Buchholz et al., 
1999).  In this system BSR/T7 cells that stably express T7 RNA polymerase were 
cotransfected with the full-length plasmid encoding the complete antigenomic RNA of 
AMPV/CO and plasmids expressing N, P, M2-1 and L proteins. A recombinant virus 
representing the full-length AMPV/CO (rAMPV/CO) was recovered using this system. 
This vaccinia-virus-free recovery system has also been used to recover several other non- 
segmented negative-stranded RNA viruses (Buchholz et al., 1999; Biacchesi et al., 2004 
and Herfst et al., 2004). Alternatively, a vaccinia-based virus recovery system has also 
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Figure 17. Cytopathic effect of recombinant AMPV/CO-GFP in Vero cells. Vero cells 
were either infected with wtAMPV/CO, rAMPV/CO, and rAMPV/CO-GFP or mock-
infected with PBS and observed for appearance of CPE characteristic of AMPV. The 
rAMPV/CO and rAMPV/CO-GFP viruses induced syncytia indistinguishable from those 
of wild type AMPV/CO, at 72 h post infection, at an MOI of 0.1. The rAMPV/CO-GFP 















igure 18. Immunostaining of Vero cells infected with rAMPV/COs. Vero cells were 
either infected with 0.1 MOI of wtAMPV/CO, rAMPV/CO, and rAMPV/CO-GFP or 
mock-infected with PBS and the infected monolayer was grown in 2 % MEM and 0.8 % 
methyl cellulose overlay. After 72 h of infection, the overlays were removed and the 
monolayers were subjected to immunoperoxidase staining. An antipeptide antibody 
raised against the N protein of AMPV/CO was utilized for the staining. The rAMPV/CO 
and rAMPV/CO-GFP viruses induced plaques indistinguishable, in morphology and 
staining characteristics, from those induced by wild type AMPV/CO.  
 
  





stomatitis virus, Lawson et al., 1995; human respiratory syncytial virus, Collins et al., 
1995; measles virus, Radecke et al., 1995; Sendai virus, Garcin et al., 1995; SV5, He et 
al., 1997; rinderpest virus, Baron and Barrett, 1997; parainfluenza virus, Hoffman and 
Banerjee, 1997; bovine respiratory syncytial virus, Yunus et al., 2001; Newcastle disease 
virus, Peeters et al., 1999 and Krishnamurthy et al., 2000; AMPV-A, Naylor et al., 2004). 
However, the former system is being utilized more increasingly due to its ease. Another 
advantage of the T7 expressing cell line is that the recombinant virus can be easily 
amplified without the vaccinia-virus associated problems. AMPV/CO is relatively slow 
growing virus compared to the vaccinia virus. Hence, in a vaccinia-virus recovery 
system, the vaccinia virus will outgrow the recombinant AMPV/CO. Hence, the T7 
expressing cell line-based virus-rescue system is more efficient to recover AMPV/CO 
entirely from cloned cDNA. 
 
The wild-type like recombinant virus rAMPV/CO, developed in this study, 
showed similar growth characteristics in tissue culture as those of its wild-type parental 
virus. The CPE induced by both wild-type AMPV/CO and rAMPV/CO in cultured Vero 
cells were very similar and the plaques formed by rAMPV/CO in Vero cells were also 
indistinguishable in size and shape from those of the parental virus. Furthermore, 
rAMPV/CO was also found to be antigenically similar to its wild-type parental virus, as 
revealed by an immunoperoxidase staining reaction of the plaques. These findings 
indicated that it is possible to recover a wild-type-virus-like recombinant virus entirely 




An important application of reverse genetics system is to engineer viruses to 
express additional foreign proteins.  Studies over the last many years have indicated the 
genome of paramyxoviruses to be very elastic and that they can be manipulated to stably 
express foreign proteins to very high levels. There are several reasons to use 
paramyxoviruses as potential virus vectors. First, the inserted foreign genes in most cases 
are expressed stably even after many passages in vitro (Bukreyev et al., 1996, Mebatsion 
et al., 1996; He et al., 1997 and Biacchesi et al., 2004a). Second, paramyxoviruses are 
safe and stable vectors since they do not show any measurable rate of homologous RNA 
recombination (Lamb and Kolakofsky, 1996 and Palese et al., 1996). However, Spann et 
al. (2003) experimentally demonstrated a low rate of intermolecular recombination in 
RSV. But the authors suggested that such low recombination events are not a concern for 
vaccine stability and safety. Third, these viruses can accommodate large foreign proteins 
and still do not show drastic reduction in growth (Sakai et al., 1999; Haglund et al., 2000 
and Huang et al., 2001 and Biacchesi et al., 2004).  Finally, attenuated strains of many 
paramyxoviruses are available for use as safe vectors.  
 
In the present study, the reverse genetics system developed by us was used to 
generate a recombinant AMPV/CO that expresses GFP (rAMPV/CO-GFP) as a foreign 
gene. GFP was inserted as a transcription cassette in putative 5' non-coding region of the 
G gene of full-length AMPV/CO cDNA. The recovered rAMPV/CO-GFP virus was 
similar to the parental virus in terms of its growth characteristics but yielded viral titers 
one-log lower than the parental virus. We also observed that rAMPV/CO stably 
expressed GFP for at least five serial passages in Vero cells. These results indicated that 
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the AMPV/CO can be genetically manipulated through reverse genetics to stably express 
foreign proteins to relatively higher levels and thus has a great potential to serve as a viral 
vector. 
 
Attenuation following expression of foreign genes has been reported among 
numerous paramyxoviruses (Krishnamurthy et al., 2000 and Biacchesi et al., 2004a). 
However, our findings showed that the insertion of GFP as a foreign gene at the G-L 
gene junction of AMPV/CO genome, did not drastically affect the replication of the 
recombinant virus. We chose GFP as the foreign gene because of the ability to directly 
visualize virus recovery and spread in the transfected cells. And at the same time, it will 
also give an indication about the vector potential of AMPV/CO. Furthermore, the ability 
to express foreign proteins from artificially inserted transcription cassette also confirmed 
the identification and functionality of the transcription signal sequences of AMPV/CO. 
This rAMPV/CO-GFP virus will also be helpful in studies involving virus tropism and 
pathogenesis. In the future, this virus can also be effectively used for the diagnosis of 
AMPV through tests such as neutralization assays, as done for HMPV (Biacchesi et al., 
2005). The recovered virus can also be used in various studies involving vaccine 
production. This recovered virus can be engineered to carry multiple foreign genes or 
immunogenic epitopes of other poultry pathogens and hence can be effectively used as a 
multivalent vaccine in poultry. In addition, through reverse genetics techniques, 
AMPV/CO can also be engineered to carry foreign proteins of viruses causing diseases in 




Although numerous paramyxoviruses have been recovered entirely from cloned 
cDNA over the past many years, the establishment of a reverse genetics system for the 
US subgroup of AMPV has considerable significance. AMPV is a recently recognized 
pathogen that has become a major problem for turkey farmers in the US. Ever since the 
initial identification of AMPV/CO in Colorado, the virus has spread to many adjoining 
states causing huge economic losses to the turkey industry. Since there are no effective 
vaccines currently available to control AMPV infections in affected birds, the 
development of a reverse genetics system is an important step for developing live-
attenuated vaccines against AMPV. Moreover, recovery of AMPV subgroup C entirely 
from cloned cDNA indicates that the viral genome can be manipulated with relative ease 
and hence this system would prove to be an effective tool in further studying AMPV 
pathogenesis and molecular biology. And, given the close resemblance between 
AMPV/CO and HMPV, our newly developed reverse genetics system will also be helpful 
in various studies involving HMPV. 
 
The ability to recover wild-type-like recombinant virus entirely from cloned 
cDNA denotes that the currently available nucleotide sequences of AMPV/CO are 
functional, at least in vitro. The recovery of a GFP-expressing recombinant AMPV/CO 
also indicates that the identified transcription signals of AMPV/CO are functional, even 
in a foreign gene concept. However, the authenticity of these sequences needs to be 
evaluated in the natural host-system, the turkeys and chickens. Our future studies focus 
on evaluating these recombinant viruses in parallel with their wild-type parental virus to 
characterize their infectivity, replication, safety, immunogenicity, and protective efficacy. 
 81 
 




With the ultimate goal of producing a recombinant live-attenuated vaccine to 
control AMPV infections in the US, we have established a reverse-genetics system for 
AMPV subgroup C strain Colorado (AMPV/CO). Information about complete genomic 
sequence of AMPV/CO is however essential for genetic manipulation. Hence, in this 
study, prior to the development of the virus rescue system, we determined the unknown 
sequences (G gene, L gene, and genomic termini) of AMPV/CO. We observed that the G 
gene of AMPV/CO is the longest known glycoprotein gene sequence among the 
metapneumoviruses. In addition, we observed considerable sequence variation in the G 
gene sequence of US isolates of AMPV-C. The L gene and the genomic termini, 
however, were very similar to the other metapneumoviruses. Our findings showed that 
the AMPV/CO genome is 14,150 nt long and possesses the longest genome among the 
metapneumoviruses.  
 
The complete genomic sequence of AMPV/CO determined by us was utilized to 
establish a reverse genetics system for AMPV/CO.  A recombinant virus, rAMPV/CO, 
representing the wild-type virus and another recombinant virus, rAMPV/CO-GFP, 
expressing GFP as a foreign protein were recovered through standard reverse genetic 
techniques. Both the recovered recombinant viruses showed growth properties similar to 
that of the wild-type virus in tissue culture, but the titer of the GFP-expressing 
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rAMPV/CO was slightly reduced when compared to the other two viruses. The 
rAMPV/CO-GFP virus expressed GFP stably for at least five serial passages in Vero 
cells. These results demonstrate that it is possible to generate recombinant AMPV/CO 
entirely from cloned cDNA through reverse genetic techniques.  
 
Ever since its identification in the US, AMPV-C has been a major problem for the 
turkey farmers. Currently, no effective vaccine is available to control AMPV infections in 
affected birds, thus leading to huge economic losses to the US turkey industry. Both live 
attenuated and killed vaccines are being used in the US to control AMPV infections in 
affected birds. However, as encountered in any live attenuated vaccine, AMPV vaccine 
may still cause disease in vaccinated birds. Moreover, the currently available live 
attenuated vaccines are empirically made and the molecular basis of attenuation is not 
known. Hence, a highly stable and efficacious vaccine becomes the ultimate objective to 
control AMPV infections in the US.  
 
Genetic engineering of AMPV/CO is needed to make a safe and effective live 
attenuated vaccine to control AMPV infections in the US. Unfortunately, the recently 
developed reverse genetic system for the European subgroup of AMPV (AMPV-A, 
Naylor et al., 2004) cannot be used to generate a live recombinant vaccine to control 
AMPV infections in the US for two main reasons:  (i) AMPV-A is distinct both 
genetically and antigenically from subgroup C and hence would not be effective against 
the latter and (ii) an AMPV-A based vaccine in the US would mean introduction of a new 
subgroup of AMPV into the US. Hence, our newly developed reverse genetics system for 
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AMPV subgroup C would be the only tool available to engineer recombinant live 
attenuated AMPV vaccine. Furthermore, the availability of the reverse genetics system 
will make it possible to understand the molecular biology and pathogenesis of AMPV-C 
and also the closely-related HMPV.  
 
5.2 Future prospects 
 The newly established reverse genetics system for AMPV/CO will have numerous 
applications. The ability to genetically manipulate the AMPV/CO genome opens many 
aspects of studying AMPV biology and its pathogenesis. Some of the potential 
applications of this infectious virus-recovery system have been discussed in the following 
sections. 
 
5.2.1 Insights into AMPV molecular biology and pathogenesis 
An important application of this reverse genetics system for AMPV/CO will be to 
study the basic molecular biology of the virus. Though the metapneumoviruses are 
similar to other paramyxoviruses in many aspects, there are few important differences in 
them that have warranted the creation of a new genus. Moreover, they are relatively a 
new group of viruses that have not been characterized well in terms of their basic 
molecular biology. Most of their characteristics are believed to be similar to other 
paramyxoviruses. However, there is not enough evidence on these aspects. Hence, we 
believe that our newly established virus-recovery system will be helpful in studying the 
molecular biology of AMPVs in further detail. The role of individual viral gene can be 
easily studied in the context of infectious virus, as opposed to studying the gene function 
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in isolation. Desired mutations or deletions can be introduced in the AMPV genome with 
relative ease and the role of viral promoters, transcription signals, non-coding regions and 
the intergenic sequences can be investigated in detail. For instance, the attachment 
glycoprotein (G) gene of AMPV/CO has been observed to be a novel one and hence the 
exact role of this gene in AMPV/CO survival and pathogenesis can be studied easily with 
this newly developed reverse genetics system.  
 
The G protein of AMPV/CO is believed to be the major viral attachment protein 
and also the major viral immunogenic protein towards which the host immune-responses 
are targeted (Seal et al., 2000). However, in HMPV it was observed that G protein is not 
essential for virus growth in tissue culture (Biacchesi et al., 2004b). Furthermore, the G-
deletion recombinant virus was also able to induce neutralizing antibodies in hamsters 
denoting that G is dispensable for protection. These results indicate that denoting that F 
protein alone is sufficient for viral replication in vivo. We have also recovered a viable 
deltaG recombinant AMPV/CO using reverse genetic techniques. We have future plans 
of studying the growth characteristics and the pathogenicity of this deltaG recombinant 
virus in turkeys. We believe that the results from these studies will provide more 
information about the functional role of the G protein of AMPV/CO. It was recently 
observed in HMPV that the F protein is the major immunogenic protein and that the 
attachment G protein is not a major protective antigen (Skiadopoulus et al., 2005). We 
strongly believe that our reverse genetics system for AMPV/CO will be helpful in 
determining the major viral protective antigen among the three surface glycoproteins F, 
SH and G.  
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We believe that the recombinant AMPV/CO that expresses GFP as a reporter 
gene will be very helpful in further studies involving AMPV pathogenesis. Our future 
plans also include utilizing this GFP-expressing virus as a trackable virus to study virus 
tropism in the natural host system – the turkeys. Furthermore, it will also have important 
diagnostic applications. The GFP-expressing AMPV/CO can be used in assays such as 
virus neutralization tests for detecting AMPV infections from field samples.  
 
5.2.2 Potential for vaccine development 
 There is an urgent need for a safe and effective vaccine to control AMPV 
infections in the US. This newly developed reverse genetics system will be a powerful 
tool for the generation of live-recombinant vaccine candidates. It will be possible to 
introduce attenuating mutations in the AMPV genome and the effect of such mutations 
on the pathogenicity of the virus can be easily evaluated. A promising candidate for 
AMPV vaccine would be a virus mutant with an altered fusion protein cleavage site. 
Recently, a cold-adapted AMPV has been shown to provide some protection against 
AMPV infections in turkeys. Another approach to generate a live-recombinant vaccine 
would be to import the mutations from this cold-adapted vaccine virus into the 
AMPV/CO genome through reverse genetic techniques and investigating the protective 
efficacy of the recovered recombinant virus. Similarly, various gene-deletion viral 
mutants can be also be generated and their potential as vaccine candidates can also be 
evaluated. A potential for creating chimeric viruses between AMPV and HMPV for use 




5.2.3 Studying the vector potential of AMPV 
 Numerous paramyxoviruses have been engineered by reverse genetic system to 
express foreign genes and thus serve as viral vectors. With the newly developed virus-
rescue system, it will be possible to design AMPV/CO to express foreign genes. The 
generation of a recombinant AMPV/CO expressing GFP was a first step towards studying 
the vector potential of AMPV/CO. The results from our present study indicate that 
though there was a slight degree of attenuation in the GFP-expressing virus, it stably 
expressed GFP for at least five serial passages in tissue culture. We believe that the one-
log reduction in the virus titer of rAMPV/CO-GFP was probably attenuation following 
insertion of GFP. We also expect that if the foreign genes are inserted at promoter 
proximal positions, as opposed to the G-L region in this case, the expression of the 
foreign gene will be higher and the resulting virus will be less attenuated. We have future 
plans to study the optimal position on the AMPV/CO genome to insert foreign genes for 
high-level expression of foreign proteins without much attenuation of the virus. In future, 
immunogenic proteins from other poultry, non-avian or human viruses can be inserted in 
the AMPV/CO genome and study the ability of AMPV to serve as a vaccine vector.  
  
5.2.4 Insights into HMPV molecular biology and pathogenesis 
 Given the close resemblance between AMPV/CO and HMPV, it can be expected 
that this newly established reverse genetic system for AMPV/CO can also be used for 
studying the molecular biology and pathogenesis of HMPV. AMPV/CO and HMPV are 
very similar in their genome organization and exhibit similar growth properties in tissue 
culture. They also produce similar disease symptoms in the affected subjects. Hence, we 
 87 
 
believe that both these viruses will also possess similar in vivo growth properties. Though 
various animal model systems have been evaluated for studying HMPV pathogenesis, an 
ideal animal model has not yet been found. Moreover, such systems do not mimic the 
natural host-system of HMPV. Non-human primates have been used in some HMPV 
pathogenesis trials. However, such experiments cannot be expected to be cost effective in 
a long run. Hence, AMPV/CO will prove to be an excellent and appropriate model 
system for studying HMPV molecular biology and pathogenesis, mainly due to the ease 
of studying the former in its natural host system. And, the newly developed reverse 
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